Organogenesis (ORGO) 10-K 1 Mar 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Feb. 15, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Document Transition Report	false
Entity Registrant Name	ORGANOGENESIS HOLDINGS INC.
Entity Central Index Key	0001661181
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Public Float			$ 1.1
Trading Symbol	ORGO
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Address, State or Province	MA
Title of 12(b) Security	Class A Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ
Document Annual Report	true
Entity Common Stock, Shares Outstanding		128,765,237
ICFR Auditor Attestation Flag	true
Entity File Number	001-37906
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	85 Dan Road
Entity Address, City or Town	Canton
Entity Address, Postal Zip Code	02021
Entity Tax Identification Number	98-1329150
City Area Code	781
Local Phone Number	575-0775
Auditor Name	RSM US LLP
Auditor Firm ID	49
Auditor Location	Boston, Massachusetts

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 113,929	$ 84,394
Restricted cash	599	412
Accounts receivable, net	82,460	56,804
Inventory	25,022	27,799
Prepaid expenses and other current assets	4,969	4,935
Total current assets	226,979	174,344
Property and equipment, net	79,160	55,792
Intangible assets, net	25,673	30,622
Goodwill	28,772	28,772
Operating lease right-of-use assets, net	49,144	0
Deferred tax asset, net	31,994	18
Other assets	1,537	670
Total assets	443,259	290,218
Current liabilities:
Current portion of deferred acquisition consideration	1,436	483
Current portion of term loan	2,656	16,666
Current portion of finance lease obligations	200	3,619
Current portion of operating lease obligations	11,785	0
Current portion of deferred rent and lease incentive obligation	0	95
Accounts payable	29,339	23,381
Accrued expenses and other current liabilities	36,589	23,973
Total current liabilities	82,005	68,217
Line of credit	0	10,000
Term loan, net of current portion	70,769	43,044
Deferred acquisition consideration, net of current portion	0	1,436
Earnout liability	0	3,985
Deferred rent and lease incentive obligation, net of current portion	0	2,315
Finance lease obligations, net of current portion	0	11,442
Operating lease obligations, net of current portion	46,893	0
Other liabilities	1,557	7,971
Total liabilities	201,224	148,410
Commitments and contingencies (Note 18)
Stockholders' equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued
Common stock, $0.0001 par value; 400,000,000 shares authorized; 129,408,740 and 128,460,381 shares issued; 128,680,192 and 127,731,833 shares outstanding at December 31, 2021 and 2020, respectively	13	13
Additional paid-in capital	302,155	296,830
Accumulated deficit	(60,133)	(155,035)
Total stockholders' equity	242,035	141,808
Total liabilities and stockholders' equity	$ 443,259	$ 290,218

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	129,408,740	128,460,381
Common stock, shares outstanding	128,680,192	127,731,833

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net revenue	$ 468,059	$ 338,298	$ 260,981
Cost of goods sold	114,199	87,319	75,948
Gross profit	353,860	250,979	185,033
Operating expenses:
Selling, general and administrative	250,200	204,193	200,088
Research and development	30,742	20,086	14,799
Total operating expenses	280,942	224,279	214,887
Income (loss) from operations	72,918	26,700	(29,854)
Other expense, net:
Interest expense	(7,236)	(11,279)	(8,996)
Gain on settlement of deferred acquisition consideration	0	2,246
Change in fair value of warrant liability			2,140
Loss on the extinguishment of debt	(1,883)		(1,862)
Other income (loss), net	(13)	97	13
Total other expense, net	(9,132)	(8,936)	(8,705)
Net income (loss) before income taxes	63,786	17,764	(38,559)
Income tax (expense) benefit	31,116	(530)	(150)
Net income (loss)	94,902	17,234	(38,709)
Non-cash deemed dividend to warrant holders			(568)
Net income (loss) attributed to common shareholders	$ 94,902	$ 17,234	$ (39,277)
Net income (loss) attributed to common shareholders, per share:
Basic	$ 0.74	$ 0.16	$ (0.42)
Diluted	$ 0.71	$ 0.15	$ (0.42)
Weighted-average common shares outstanding
Basic	128,331,022	107,737,936	92,840,401
Diluted	133,662,659	111,360,831	92,840,401

CONSOLIDATED STATEMENTS OF REDE

CONSOLIDATED STATEMENTS OF REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY - USD ($)	Total	Previously Reported [Member]	Revision of Prior Period, Accounting Standards Update, Adjustment [Member]	Revision of Prior Period, Reclassification, Adjustment [Member]	Redeemable Common Stock	Redeemable Common StockPreviously Reported [Member]	Common Stock	Common StockPreviously Reported [Member]	Additional Paid-in Capital	Additional Paid-in CapitalPreviously Reported [Member]	Additional Paid-in CapitalRevision of Prior Period, Reclassification, Adjustment [Member]	Accumulated Deficit	Accumulated DeficitPreviously Reported [Member]	Accumulated DeficitRevision of Prior Period, Accounting Standards Update, Adjustment [Member]	Accumulated DeficitRevision of Prior Period, Reclassification, Adjustment [Member]
Balance at Dec. 31, 2018	$ 39,939,000	$ 47,041,000	$ 332,000		$ 728,548,000	$ 728,548,000	$ 9,000	$ 9,000	$ 173,254,000	$ 177,272,000		$ (133,324,000)	$ (130,240,000)	$ 332,000
Balance (in shares) at Dec. 31, 2018							91,261,413	91,261,413
Exercise of common stock warrants	628,000								628,000
Exercise of common stock warrants (in shares)							74,052
Exercise of stock options	269,000								269,000
Exercise of stock options (in shares)							152,133
Common stock issued in warrant exchange	1,796,000								2,364,000			(568,000)
Common stock issued in warrant exchange (shares)							3,315,232
Stock-based compensation expense	936,000								936,000
Adjustment due to Private Warrant reclassification				$ (3,936,000)							$ (4,018,000)				$ 82,000
Adjustment due to right of use asset amortization				$ (3,166,000)											$ (3,166,000)
Redemption of redeemable common stock placed into treasury (in shares)					(728,548)
Shares issued in the underwritten public offering	46,831,000						$ 1,000		46,830,000
Shares issued in the underwritten public offering (in shares)							10,068,056
Net income (loss)	(38,709,000)											(38,709,000)
Balance at Dec. 31, 2019	52,022,000						$ 10,000		224,281,000			(172,269,000)
Balance (in shares) at Dec. 31, 2019							104,870,886
Exercise of stock options	2,823,000						$ 1,000		2,822,000
Exercise of stock options (in shares)							996,286
Stock-based compensation expense	1,661,000								1,661,000
Issuance of common stock associated with business acquisition	7,986,000								7,986,000
Issuance of common stock associated with business acquisition (in shares)							1,947,953
Shares issued in the underwritten public offering	60,082,000						$ 2,000		60,080,000
Shares issued in the underwritten public offering (in shares)							19,916,708
Net income (loss)	17,234,000											17,234,000
Balance at Dec. 31, 2020	$ 141,808,000	$ 146,084,000					$ 13,000		296,830,000			(155,035,000)
Balance (in shares) at Dec. 31, 2020	127,731,833						127,731,833
Exercise of stock options	$ 2,198,000								2,198,000
Exercise of stock options (in shares)	955,736						760,458
Stock-based compensation expense	$ 3,864,000								3,864,000
Vesting of RSUs, net of shares surrendered to pay taxes	(737,000)								(737,000)
Vesting of RSUs, net of shares surrendered to pay taxes (in shares)							187,901
Net income (loss)	94,902,000											94,902,000
Balance at Dec. 31, 2021	$ 242,035,000						$ 13,000		$ 302,155,000			$ (60,133,000)
Balance (in shares) at Dec. 31, 2021	128,680,192						128,680,192

CONSOLIDATED STATEMENTS OF RE_2

CONSOLIDATED STATEMENTS OF REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Issuance costs	$ 4,647	$ 3,510

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ 94,902	$ 17,234	$ (38,709)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation	5,781	4,438	3,783
Amortization of intangible assets	4,949	3,745	6,043
Amortization of operating lease right-of-use assets	5,946
Non-cash interest expense	346	236	243
Deferred interest expense	1,493	2,133	1,446
Deferred rent expense		1,273	882
Gain on settlement of deferred acquisition consideration	0	(2,246)
Deferred tax expense (benefit)	(31,976)	112	111
Loss on disposal of property and equipment	1,407	201	146
Provision recorded for doubtful accounts	2,999	1,183	239
Adjustment for excess and obsolete inventories	12,079	3,050	1,297
Stock-based compensation	3,864	1,661	936
Loss on extinguishment of debt	1,883		1,862
Change in fair value of Earnout liability	(3,985)	203
Change in fair value of warrant liability			(2,140)
Changes in operating assets and liabilities:
Accounts receivable	(28,654)	(17,567)	(4,691)
Inventory	(9,302)	(6,700)	(11,063)
Prepaid expenses and other current assets	(34)	(355)	(625)
Operating leases	(6,156)
Accounts payable	3,847	(4,102)	4,700
Accrued expenses and other current liabilities	8,654	1,443	2,942
Other liabilities	(6,065)	(476)	(930)
Net cash provided by (used in) operating activities	61,978	5,466	(33,528)
Cash flows from investing activities:
Purchases of property and equipment	(31,220)	(17,678)	(5,984)
Cash paid for business acquisition		(5,820)
Acquisition of intangible asset			(250)
Net cash used in investing activities	(31,220)	(23,498)	(6,234)
Cash flows from financing activities:
Line of credit borrowings (repayments), net	(10,000)	(23,484)	7,000
Term loan borrowings (repayments) under the 2019 Credit Agreement, net of debt discount and issuance cost	(60,000)	10,000	49,076
Proceeds from term loan under the 2021 Credit Agreement, net of debt discount and issuance cost	73,174
Term loan repayments under the 2021 Credit Agreement	(938)
Proceeds from equity financing		64,729	50,340
Payment of equity issuance costs		(5,656)	(2,973)
Repayment of notes payable			(17,585)
Principal repayments of capital lease obligations	(2,630)	(2,427)	(1,266)
Redemption of redeemable common stock placed into treasury			(6,762)
Proceeds from the exercise of stock options	2,198	2,823	269
Proceeds from the exercise of common stock warrants			628
Payments of withholding taxes in connection with RSUs vesting	(737)
Payments of deferred acquisition consideration	(483)	(3,517)
Payment to extinguish debt	(1,620)
Net cash provided by (used in) financing activities	(1,036)	42,468	78,727
Change in cash and restricted cash	29,722	24,436	38,965
Cash and restricted cash, beginning of year	84,806	60,370	21,405
Cash and restricted cash, end of year	114,528	84,806	60,370
Supplemental disclosure of cash flow information:
Cash paid for interest	5,787	9,609	8,148
Cash paid for income taxes	607	61	49
Supplemental disclosure of non-cash investing and financing activities:
Reimbursement of offering expenses included in prepaid expenses and other current assets	0	1,009
Fair value of shares issued for business acquisition		7,986
Deferred acquisition consideration and earnout liability recorded for business acquisition		5,218
Non-cash deemed dividend related to warrant exchange			568
Equity issuance costs included in accounts payable			537
Purchases of property and equipment in accounts payable and accrued expenses	3,750	$ 2,391	4,014
Acquisition of intangible assets included in accrued expenses and other liabilities			500
Right-of-use assets obtained through lease obligations	$ 53,793		$ 1,099

Nature of Business and Basis of

Nature of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	1. Nature of Business and Basis of Presentation Organogenesis Holdings Inc. (formerly Avista Healthcare Public Acquisition Corp.) (“ORGO” or the “Company”) is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Several of the existing and pipeline products in the Company’s portfolio have Premarket Application (“PMA”) approval, or Premarket Notification 510(k) clearance from the United States Food and Drug Administration (“FDA”). The Company’s customers include hospitals, wound care centers, government facilities, ambulatory service centers (“ASCs”) and physician offices. The Company has one operating and reportable segment. COVID-19 The coronavirus (COVID-19) COVID-19 COVID-19

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Significant Accounting Policies Revision to Previously Issued Financial Statements Private Warrant Reclassification On April 12, 2021, the Staff of the SEC issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). In the SEC Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s financial statements as opposed to equity. As of December 31, 2018, the Company had 4.1 million private warrants outstanding, which were issued to Avista Capital Partners IV, L.P. and Avista Capital Partners IV (Offshore), L.P. in connection with the Avista Merger on December 10, 2018 (the “Private Warrants”), and 31.0 million public warrants outstanding that were issued in connection with the initial public offering of Avista Healthcare Public Acquisition Corp. on October 10, 2016 (the “Public Warrants”, together with the Private Warrants, the “Warrants”). The Company originally classified the Warrants as equity on its financial statements. In 2019, the outstanding Warrants were exchanged for 3.3 million shares of the Company’s Class A common stock (see Note “13. Stockholders’ Equity”. There were no Warrants outstanding as of December 31, 2019. As a result of the SEC Statement, the Company reevaluated the historical accounting treatment of its Public Warrants and Private Warrants and determined that the Private Warrants should have been recorded at fair value as a liability in the Company’s consolidated balance sheet with changes to the fair value recorded to the consolidated statements of operations. The Company assessed the materiality of this error on prior period financial statements in accordance with the SEC Staff Accounting Bulletin Number 99, Materiality, and ASC 250-10, Right of Use Asset Amortization In August 2021, the Company identified an error in its accounting treatment for two assets recorded as finance leases. The Company did not record amortization expenses for these assets since the lease commencement date. This error resulted in an overstatement of property and equipment, net, and an understatement of accumulated deficit, and selling, general and administrative expenses in the financial statements included in the Company’s quarterly reports on Form 10-Q 10-K ASC 250-10, To correct the misstatements above, the Company revised its previously issued financial statements as follows: As of December 31, 2020 CONSOLIDATED BALANCE SHEETS As Previously Adjustments As Revised Property and equipment, net $ 60,068 $ (4,276 ) $ 55,792 Total assets $ 294,494 $ (4,276 ) $ 290,218 Additional paid-in $ 299,129 $ (2,299 ) $ 296,830 Accumulated deficit $ (153,058 ) $ (1,977 ) $ (155,035 ) Total stockholders’ equity $ 146,084 $ (4,276 ) $ 141,808 Total liabilities and stockholders’ equity $ 294,494 $ (4,276 ) $ 290,218 For the Year Ended December 31, 2020 For the Year Ended December 31, 2019 CONSOLIDATED STATEMENTS OF OPERATIONS As Adjustments As Revised As Adjustments As Revised Selling, general and administrative $ 203,478 $ 715 $ 204,193 $ 199,693 $ 395 $ 200,088 Total operating expenses $ 223,564 $ 715 $ 224,279 $ 214,492 $ 395 $ 214,887 Income from operations $ 27,415 $ (715 ) $ 26,700 $ (29,459 ) $ (395 ) $ (29,854 ) Change in fair value of warrant liability $ — $ 2,140 $ 2,140 Total other expense, net $ (10,845 ) $ 2,140 $ (8,705 ) Net income (loss) before income taxes $ 18,479 $ (715 ) $ 17,764 $ (40,304 ) $ 1,745 $ (38,559 ) Net income (loss) $ (40,454 ) $ 1,745 $ (38,709 ) Non-cash deemed $ (645 ) $ 77 $ (568 ) Net income (loss) attributed to common shareholders $ 17,949 $ (715 ) $ 17,234 $ (41,099 ) $ 1,822 $ (39,277 ) Net income (loss), per share: Basic $ 0.17 $ 0.16 $ (0.44 ) $ (0.42 ) Diluted $ 0.16 $ 0.15 $ (0.44 ) $ (0.42 ) For the Year Ended December 31, 2020 CONSOLIDATED STATEMENTS OF CASH FLOWS As Previously Adjustments As Revised Net loss $ 17,949 $ (715 ) $ 17,234 Depreciation $ 3,723 $ 715 $ 4,438 Recovery of certain notes receivable from related parties $ (1,516 ) $ 1,516 $ — Prepaid expenses and other current assets $ (971 ) $ 616 $ (355 ) Accounts payable $ (635 ) $ (3,467 ) $ (4,102 ) Net cash provided by (used in) operating activities $ 6,801 $ (1,335 ) $ 5,466 Purchases of property and equipment $ (21,145 ) $ 3,467 $ (17,678 ) Proceeds from the repayment of notes receivable from related parties $ 2,132 $ (2,132 ) $ — Net cash used in investing activities $ (24,833 ) $ 1,335 $ (23,498 ) For the Year Ended December 31, 2019 CONSOLIDATED STATEMENTS OF CASH FLOWS As Previously Adjustments As Revised Net loss $ (40,454 ) $ 1,745 $ (38,709 ) Depreciation $ 3,388 $ 395 $ 3,783 Change in fair value of warrant liability $ — $ (2,140 ) $ (2,140 ) Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported results of operations during the reporting periods. In preparing the consolidated financial statements, the estimates and assumptions that management consider to be significant and that present the greatest amount of uncertainty include revenue recognition; sales returns and credit losses; inventory reserve; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite lived assets (including intangible assets), assessing impairment of goodwill; valuation of assets and liabilities that use unobservable inputs, and the valuation and recognition of stock-based compensation. Actual results and outcomes may differ significantly from those estimates and assumptions. Principles of Consolidation The consolidated financial statements include the accounts and results of operations of Organogenesis Holdings Inc., and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Segment Reporting Operating segments are defined as components of an enterprise about which discrete financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance for the organization. The Company’s chief operating decision maker is the Chief Executive Officer. The Company’s chief operating decision maker reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. Accordingly, the Company has determined that it has a single operating segment—regenerative medicine. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s portfolio includes regenerative medicine products in various stages, ranging from preclinical to late stage development, and commercialized advanced wound care and surgical and sports medicine products which support healing across a wide variety of wound types at many different types of facilities. Cash and Cash Equivalents The Company primarily maintains its cash in bank deposit accounts in the United States which, at times, may exceed the federally insured limits. The Company has not experienced losses in such accounts and believes it is not exposed to significant credit risk on cash. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Restricted Cash The Company had restricted cash of $599 and $412 as of December 31, 2021 and 2020, respectively. Restricted cash represents employee deposits in connection with the Company’s health benefit plan. Accounts Receivable, Net Accounts receivable are stated at invoice value less estimated allowances for doubtful accounts. The Company continually monitors customer payments and maintains a reserve for estimated losses resulting from its customers’ inability to make required payments. The Company considers factors when estimating the allowance for doubtful accounts such as historical experience, credit quality, age of the accounts receivable balances, geography-related risks and economic conditions that may affect a customer’s ability to pay. In cases where there are circumstances that may impair a specific customer’s ability to meet its financial obligations, a specific allowance is recorded against amounts due, thereby reducing the net recognized receivable to the amount reasonably believed to be collectible. Accounts receivables are written off when deemed uncollectible. Recoveries of accounts receivables previously written off are recorded when received. Inventories Inventories are stated at the lower of cost (determined under the first-in first-out The Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value based upon management’s assumptions of future material usage, yields and obsolescence, which are a result of future demand and market conditions and the effective life of certain inventory items. The Company also tests other components of its inventory for future growth projections. The Company determines the average yield of the component and compares it to projected revenue to ensure it is properly reserved. Property and Equipment, Net Property and equipment are recorded at cost and depreciated over the estimated useful lives of the respective assets on a straight-line basis. As of December 31, 2021 and 2020, the Company’s property and equipment consisted of leasehold improvements, building, furniture and computers, and equipment. Property and equipment’s estimated useful lives are as follows: Leasehold improvements Lesser of the life of the lease or the economic life of the asset Building 30 years Furniture and computers 3-5 years Equipment 5-10 years Upon retirement or sale, the cost of assets disposed of, and the related accumulated deprecia tion Goodwill Goodwill represents the excess of the purchase price of an acquired business over the fair value of the identifiable assets acquired and liabilities assumed. Goodwill is not amortized, but is tested for impairment at least annually (as of December 31), or more frequently if events or circumstances indicate the carrying value may no longer be recoverable and that an impairment loss may have occurred. Circumstances that could trigger an impairment test include, but are not limited to, a ++significant adverse change in the business climate or legal factors, an adverse action or assessment by a regulator, or unanticipated competition. The Company operates as one segment, which is considered to be the sole reporting unit, and therefore goodwill is tested for impairment at the consolidated level. In accordance with ASC Topic 350, Intangibles—Goodwill and Other, There was no impairment of goodwill recorded during the years ended December 31, 2021, 2020, or 2019. Intangible Assets Subject to Amortization Intangible assets include intellectual property either owned by the Company or for which the Company has a license. Intangible assets acquired in a business combination are recognized at fair value using generally accepted valuation methods deemed appropriate for the type of intangible asset acquired. Intangible assets are reported net of accumulated amortization, separately from goodwill. Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets include developed technology and patents, trade names, trademarks, customer relationships and non-compete Trade names and trademarks 1-12 Developed technology 6-12 Customer relationships 10 years Non-compete 5 years Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment and intangible assets. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include, but not limited to, significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. When such an event occurs, the Company determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the related asset group’s carrying value. If an asset is determined to be impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not record any impairment of long-lived assets during the years ended December 31, 2021, 2020, or 2019. Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process The Company did not record any deferred offering costs in the consolidated balance sheets as of December 31, 2021 and 2020. During the year ended December 31, 2020 and 2019, the Company recorded $4,647 and $3,510 of equity issuance costs to additional paid-in Revenue Recognition Product Revenue The Company generates revenue through the sale of Advanced Wound Care and Surgical & Sports Medicine products. There is a single performance obligation in all of the Company’s contracts, which is the Company’s promise to transfer the Company’s product to customers based on specific payment and shipping terms in the arrangement. The entire transaction price is allocated to this single performance obligation. Product revenue is recognized when a customer obtains control of the Company’s product which occurs at a point in time and may be upon shipment, procedure date, or delivery, based on the terms of the contract. Reserves for Variable Consideration Revenues from product sales are recorded net of reserves for variable consideration which includes but is not limited to product return, discounts, rebates and group purchasing organization (“GPO”) fees that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed by its customers on the related sales and are recorded as a reduction of accounts receivable or an establishment of a liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract and is included in the net sales price to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately paid may differ from the Company’s estimates. If actual results vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Product Returns Consistent with industry practice, the Company generally offers customers a limited right of return for product purchased. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return reserves using its historical return rates as well as factors that it becomes aware of that it believes could significantly impact its expected returns, including product recalls, pricing changes, or change in reimbursement rates. The Company does not record an asset for the returned product as the product is discarded upon receipt. Rebates and Allowances The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts, resulting in a reduction of revenue and the establishment of a liability that is included in accrued expenses in the accompanying consolidated balance sheets in the period the related product revenue is recognized. GPO Fees The Company pays fees to GPOs for administrative services that the GPOs perform in connection with the purchases of the product by the GPO members. These fees are based on a contractually-determined percentage of the Company’s applicable sales. The Company classifies these GPO fees as a reduction of revenue based on the substance of the relationship of all parties involved in the transaction. For the years ended December 31, 2021, 2020, and 2019, the Company recorded GPO fees of $2,963, $3,572, and $3,096, respectively, as a direct reduction of revenue. Other Revenue Policies Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Applying the practical expedient in paragraph ASC 606-10-32-18, Applying the practical expedient in ASC 340-40-25-4, Applying the practical expedient in ASC 606-10-25-18B, Disaggregation of Revenue The following table sets forth revenue by product category: Year Ended December 31, 2021 2020 2019 Advanced Wound Care revenue $ 430,839 $ 294,624 $ 220,744 Surgical and Sports Medicine revenue 37,220 43,674 40,237 Total revenue $ 468,059 $ 338,298 $ 260,981 For all periods presented, net revenue generated outside the United States represented less than 1% of total net revenue.​​​​​​​ Stock-Based Compensation The Company measures stock-based awards granted based on the fair value of the awards on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Generally, the Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance-based vesting conditions. The Company recognizes stock-based compensation expense within selling, general and administrative expenses in the consolidated statement of operations for all share-based payments based upon the estimated grant-date fair value for the awards expected to ultimately vest. The fair value of each restricted stock unit grant is based on the fair market value of the Company’s stock on the date of grant. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company has been a public company for a short period of time, has limited public float and lacks company-specific historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on its Class A common stock and does not expect to pay any cash dividends in the foreseeable future. Advertising Advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of operations. Advertising costs were approximately $5,522, $2,722, and $1,059 for the years ended December 31, 2021, 2020, and 2019, respectively. Research and Development Costs Research and development expenses include personnel costs for the Company’s research and development personnel, expenses related to improvements to manufacturing processes, enhancements to the Company’s currently available products, and additional investments in the product and platform development pipeline. Research and development expenses also include expenses for clinical trials. The Company expenses research and development costs as incurred. Foreign Currency The Company’s functional currency, including the Company’s Swiss subsidiary, Organogenesis GmbH, is the U.S. dollar. Foreign currency gains and losses resulting from re-measurement of as non-operating income Valuation of Contingent Purchase Earnout In connection with the acquisition of CPN Biosciences, LLC (“CPN”), the Company recognized a non-current liability for the fair value of the contingent consideration (the “Earnout”) at the time of the acquisition in 2020. The Earnout liability is classified as a Level 3 measurement for which fair value is derived from inputs that are unobservable and significant to the overall fair value measurement. The fair value of such Earnout liability is estimated using a Monte Carlo simulation model that utilizes key assumptions including forecasted revenues and volatilities of the underlying financial metrics during the Earnout period. The Company assesses the fair value of the Earnout liability at each reporting period. Any subsequent changes in the estimated fair value of the liability are reflected in selling, general and administrative expenses until the liability is settled. Income Taxes The Company accounts for income taxes using the asset and liability method which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statement and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company quarterly assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. In determining whether a valuation allowance for deferred tax assets is necessary, we analyze both positive and negative evidence related to the realization of deferred tax assets , including projected future taxable income, recent financial results and estimates of future reversals of deferred tax assets and liabilities. In the fourth quarter of 2021, we determined it was more likely than not that our deferred tax assets would be realized in the future and released the valuation allowance on our net deferred tax assets as of December 31, 2021, resulting in a benefit in income taxes. See Note “15. Income Taxes.” The Company accounts for uncertain income tax positions recognized in the consolidated financial statements by applying a two-step more-likely-than-not Fair Value of Financial Instruments Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values of accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Earnout liability was carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above (see Note “4. Fair Value Measurement of Financial Instruments”). The carrying values of outstanding borrowings under the Company’s debt arrangements “12. Long-Term Debt Obligations”) approximate their fair values as determined based on a discounted cash flow model, which represents a Level 3 measurement.​​​​​​​ Net Income (Loss) per Share The Company determines net income (loss) per share in accordance with the authoritative guidance in ASC Topic 260, Earnings Per Share Emerging Growth Company Before December 31, 2021, the Company was an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company elected to use the extended transition period for complying with new or revised accounting standards (such as ASU 2016-02, Leases Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-02 2016-02”), Leases Topic 842), right-of-use Leases months or less. The Company also elected to account for lease components and the associated non-lease right-of-use right-of-use de-recognition In December 2019, the FASB issued ASU No. 2019-12, Income Taxes—Simplifying the Accounting for Income Taxes 2019-12 Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Subsequent ASU 2016-13, the ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging and Topic 825 Financial Instruments ASU 2019-05, Financial Instruments—Credit Losses (Topic 326)—Targeted Transition Relief ASU 2019-11, Codification Improvements to Topic 326 Financial Instruments—Credit Losses ASU 2016-13 and ASU 2016-13 and ASU 2016-13 In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting 2020-04”). 2020-04 No. 2021-01, Reference Rate Reform (Topic 848): Scope 2021-01”), 2020-04 2021-01 through December 31, 2022. The Company’s debt agreement that utilizes LIBOR has conventional LIBOR replacement language. Since the debt agreement has not discontinued the use of LIBOR, this ASU is not yet effective for the Company. To the extent the interest rate changes to the rate specified in the debt agreement , the Company will utilize the relief in this ASU. The Company evaluated the effects of adopting the provisions of ASU 2020-04 2021-01

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Acquisition	3. Acquisition On September 17, 2020 (the “Acquisition Date”), the Company acquired certain assets and assumed certain liabilities of CPN Biosciences, LLC (“CPN”) pursuant to an asset purchase agreement dated July 24, 2020. CPN offered a physician office management solution and advanced wound care products. The aggregate consideration amounted to $19,024 as of the Acquisition Date, consisting of $6,427 in cash, 2,151,438 shares of the Company’s Class A common stock with a fair value of $8,815, and contingent consideration (the “Earnout”) with a fair value of $3,782. On the Acquisition Date, the Company paid $5,820 in cash and issued 1,947,953 shares of the Company’s Class A common stock. The remaining consideration of $1,436 was held back (the “Holdback”) and will be paid or issued, as applicable, eighteen months after the Acquisition Date, subject to any offsetting indemnification claims against CPN. The Company is obligated to pay the Earnout to CPN’s former shareholders if CPN’s legacy product revenue in the Earnout Period (July 1, 2021 to June 30, 2022), exceeds CPN’s 2019 revenue. The amount of the Earnout, if any, will be equal to 70% of the excess and will be payable 60 days after the expiration of the Earnout Period. The Company recorded a non-current

Fair Value Measurement of Finan

Fair Value Measurement of Financial Instruments	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurement of Financial Instruments	4. Fair Value Measurement of Financial Instruments The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2021 and 2020. Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Liabilities: Earnout liability $ — $ — $ — $ — $ — $ — $ — $ — Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Liabilities: Earnout liability $ — $ — $ 3,985 $ 3,985 $ — $ — $ 3,985 $ 3,985 Earnout Liability In connection with accounting for the CPN acquisition on September 17, 2020, the Company recorded an Earnout liability of $3,782 on the Acquisition Date, representing the fair value of contingent consideration payable upon the achievement of a certain revenue target. The Earnout liability is classified as a Level 3 measurement within the fair value hierarchy for which fair value is derived from inputs that are unobservable and significant to the overall fair value measurement. The fair value of such Earnout liability is estimated using a Monte Carlo simulation model that utilizes key assumptions including forecasted revenues and volatilities of the underlying financial metrics during the Earnout Period. The Company assesses the fair value of the Earnout liability at each reporting period. Any subsequent changes in the estimated fair value of the liability are reflected in selling, general and administrative expenses until the liability is settled. For more information about the Earnout liability, refer to Note “3. Acquisition”. As of December 31, 2021, the Earnout liability decreased to $0 as a result of the Company’s updated assessment of the near-term market for the CPN product portfolio. The following table provides a roll-forward of the fair value of the Company’s Earnout liability, for which fair value is determined using Level 3 inputs: Earnout Balance as of December 31, 2019 $ — Acquisition Date fair value 3,782 Change in fair value 203 Balance as of December 31, 2020 3,985 Change in fair value (3,985 ) Balance as of December 31, 2021 $ — Warrant Liability In connection with the Avista Merger, the Company issued 4.1 million private warrants to Avista Capital Partners IV, L.P. and Avista Capital Partners IV (Offshore), L.P. on December 10, 2018 (the “Private Warrants”). The Company classified the warrants as a liability on the consolidated balance sheets as the settlement provisions of the Private Warrants failed the “fixed-for-fixed” ASC815-40-15-7 The Private Warrants were settled in the warrant exchange transactions in the third quarter of 2019, with a decrease of 2,140 in the fair value recognized as a component of other expense, net in the consolidated statements of operation for the year ended 2019. Warrant Balance as of December 31, 2019 $ 3,936 Change in fair value (2,140 ) Settled in warrant exchange transaction (1,796 ) Balance as of December 31, 2020 $ — The Company did not have any financial assets and liabilities measured at fair value on a non-recurring and 2020.

Accounts receivable, net

Accounts receivable, net	12 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Accounts receivable, net	5. Accounts receivable, net Accounts receivable consisted of the following: December 31, 2021 2020 Accounts receivable $ 87,613 $ 59,473 Less—allowance for doubtful accounts (5,153 ) (2,669 ) $ 82,460 $ 56,804 The Company’s allowance for doubtful accounts was comprised of the following: Balance as of December 31, 2019 $ 1,988 Additions 1,183 Write-offs (502 ) Balance as of December 31, 2020 $ 2,669 Additions 2,999 Write-offs (515 ) Balance as of December 31, 2021 $ 5,153

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	6. Inventories Inventories, net of related reserves, consisted of the following: December 31, 2021 2020 Raw materials $ 9,023 $ 10,075 Work in process 991 1,305 Finished goods 15,008 16,419 $ 25,022 $ 27,799 Raw materials include various components used in the Company’s manufacturing process. The Company’s excess and obsolete inventory review process includes analysis of sales forecasts and historical sales as compared to inventory levels $ The significant increase in inventory excess and obsolescence charge is due to certain inventory with very short shelf life and uncertain production yield.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Prepaid Expenses and Other Current Assets	7. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: December 31, 2021 2020 Subscriptions $ 2,745 $ 2,013 Conferences and marketing expenses 538 63 Deposits 1,216 1,438 Reimbursement of offering expenses — 1,009 Insurance 358 240 Other 112 172 $ 4,969 $ 4,935 Deposits are funds held by vendors which are expected to be released within twelve months and therefore they are recorded as current assets.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	8. Property and Equipment, Net Property and equipment consisted of the following: December 31, 2021 2020 Leasehold improvements $ 30,531 $ 39,574 Building 4,943 — Furniture, computers and equipment 53,959 48,236 89,433 87,810 Accumulated depreciation and amortization (57,729 ) (73,797 ) Construction in progress 47,456 41,779 $ 79,160 $ 55,792 Depreciation expense was $5,781, $4,438, and $3,783, for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2020, the Company had $21,689 of buildings under finance leases recorded within leasehold improvements and had $18,716 recorded within accumulated depreciation related to these buildings. In August 2021, the Company purchased one building previously under a finance lease from a related party and removed the building from leasehold improvements and recorded the asset to buildings. In November 2021, the Company exercised the option to extend the leases of the other buildings previously under finance leases for additional five years. These leases were reclassified from finance leases to operating leases upon the Company’s reassessment of the lease classification according to ASC 842-10-25-1 Lease Classification. lease right-of-use assets Construction in progress primarily represents unfinished construction work on the aforementioned purchased building and, more recently, improvements at the Company’s leased facilities in Canton and Norwood, Massachusetts.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets Goodwill was $28,772 as of December 31, 2021 and 2020. Identifiable intangible assets consisted of the following as of December 31, 2021: Original Accumulated Amortization Net Book Value Developed technology $ 32,620 $ (17,709 ) $ 14,911 Trade names and trademarks 2,080 (1,183 ) 897 Customer relationship 10,690 (1,381 ) 9,309 Independent sales agency network 4,500 (4,500 — Patent 7,623 (7,623 — Non-compete 1,010 (454 ) 556 Total $ 58,523 $ (32,850 ) $ 25,673 Identifiable intangible assets consisted of the following as of December 31, 2020: Original Accumulated Net Book Value Developed technology $ 32,620 $ (14,330 ) $ 18,290 Trade names and trademarks 2,080 (906 ) 1,174 Customer relationship 10,690 (312 ) 10,378 Independent sales agency network 4,500 (4,500 — Patent 7,623 (7,623 — Non-compete 1,010 (230 ) 780 Total $ 58,523 $ (27,901 ) $ 30,622 Amortization of intangible assets, calculated on a straight-line basis or using an accelerated method, which reflects the pattern in which the economic benefits of the intangible assets are consumed, was $4,949, $3,745 , and $6,043 for the years ended December 31, 2021, 2020, and 2019, respectively. Estimated future annual amortization expense related to these intangible assets is as follows: 2022 $ 4,883 2023 4,918 2024 3,403 2025 3,323 2026 3,043 Thereafter 6,103 Total $ 25,673

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	10. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: December 31, 2021 2020 Personnel costs $ 26,865 $ 18,943 Royalties 3,458 2,971 Accrued but unpaid lease obligations and interest 3,963 — Other 2,303 2,059 $ 36,589 $ 23,973 The accrued but unpaid lease obligations and the interest accrual on these obligations were previously included in the long-term portion of the finance lease obligations, and other liabilities as of December 31, 2020. The reclassification was due to the purchase of a building previously recorded as a finance lease from a related party (see Note “17. Leases”) and the termination of the 2019 Credit Agreement (see Note “12. Long-Term Debt Obligations”).​​​​​​​

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring	11. Restructuring On October 21, 2020, the Company committed to a plan to restructure the workforce and consolidate its La Jolla facilities as part of the Company’s long-term plan to consolidate manufacturing operations into Massachusetts to reduce the Company’s cost structure. The majority of the restructuring costs have been incurred as of December , , with certain facility and storage costs continuing through the middle of . The restructuring will result in a charge of approximately $ million, of which approximately $ million is attributable to the retention benefits associated with approximately employees and the remaining $ million is related to the facility closures. As employees are required to provide future services, employee retention and other benefit-related costs related to the Company’s restructuring are expensed over the service period. As a result of this restructuring activity, the Company incurred a pre-tax charge of $4,704 and $618 in the year ended December 31, 2021 and 2020, respectively. These charges were included in selling, general and administrative expenses in the consolidated statements of operations. The liability related to the restructuring activities was $3,168 and $618 as of December 30, 2021 and 2020, respectively, and was included in accrued expenses and other current liabilities in the consolidated balance sheets. The following table provides a roll-forward of the restructuring liability.​​​​​​​ Employee Facility Liability balance as of December 31, 2019 $ — $ — Expenses 618 — Cash distributions — — Liability balance as of December 31, 2020 618 — Expenses 3,513 1,191 Cash distributions (1,614 ) (540 ) Liability balance as of December 31, 2021 $ 2,517 $ 651

Long-Term Debt Obligations

Long-Term Debt Obligations	12 Months Ended
	Dec. 31, 2021
Long-term Debt, Unclassified [Abstract]
Long-Term Debt Obligations	12. Long-Term Debt Obligations December 31, 2021 2020 Line of credit $ — $ 10,000 Term loan 74,062 60,000 Less debt discount and debt issuance cost (637 ) (290 ) Term loan, net of debt discount and debt issuance cost $ 73,425 $ 59,710 2021 Credit Agreement In August 2021, the Company, as borrower, its subsidiaries, as guarantors, a nd Silicon Credit Agreement. Advances made under the 2021 Credit Agreement may be either Eurodollar Loans or ABR Loans, at the Company’s option. For Eurodollar Loans, the interest rate is a per annum interest rate equal to LIBOR plus an Applicable Margin between 2.00% to 3.25% based on the Total Net Leverage Ratio. For ABR Loans, the interest rate is equal to (1) the highest of (a) the Wall Street Journal Prime Rate, (b) the Federal Funds Rate plus 0.50 plus The be re-borrowed. The Company must pay in arrears, on the first day of each quarter prior to August 6, 2026 (the “Revolving Termination Date”) and on the Revolving Termination Date, a fee for the Company’s non-use of in an amount equal to the Commitment Fee Rate per annum, multiplied by the difference between (x) the Total Revolving Commitments and (y) the sum of (i) the average for the period of the daily closing balance of the Revolving Loans, excluding the aggregate principal amount of Swingline Loans, (ii) the aggregate undrawn amount of all Letters of Credit outstanding at such time and (iii) the aggregate amount of all L/C Disbursements that have not yet been reimbursed or converted into Revolving Loans or Swingline Loans. The Commitment Fee Rate is between to based on the Total Net Leverage Ratio. The maturity date for advances made under the Revolving Facility is the Revolving Termination Date. The Company may elect to reduce or terminate the Revolving Facility in its entirety at any time by repaying all outstanding principal, unpaid accrued interest and, with respect to any such reduction or termination of the Revolving Commitments made prior to August 6, 2022, of the aggregate amount of the Revolving Commitments so reduced or terminated. Under the 2021 Credit Agreement, the Company is required to comply with certain financial covenants including the Consolidated Fixed Charge Coverage Ratio and Consolidated Total Net Leverage Ratio, tested quarterly. In addition, the Company is also required to make representations and warranties and comply with certain non-financial As of December 31, 2021, the Company had outstanding borrowings of $74,062 under the Term Loan Facility and $0 under the Revolving Facility with $125,000 available for future revolving borrowings. The Company recorded additional debt issuance costs and related fees of $604 in connection with the Term Loan Facility, which are recorded as a reduction of the carrying value of the term loan on the Company’s consolidated balance sheets. In connection with the Revolving Facility, the Company recorded debt issuance costs and related fees of $1,223, which are recorded as other assets. Both of these costs are being amortized to interest expense through the maturity date of the facilities.​​​​​​​​​​​​​​ Future payments of the 2021 Credit Agreement, as of December 31, 2021, are as follows for the calendar years ending December 31: 2022 $ 2,812 2023 4,687 2024 5,625 2025 6,563 2026 and beyond 54,375 Total $ 74,062 2019 Credit Agreement In March 2019, the Company, its subsidiaries and SVB, and the several other lenders thereto entered into a credit agreement, as amended (the “2019 Credit Agreement”), providing for a term loan facility of $40,000 and a revolving credit facility of up to $60,000. Both facilities were set to mature in 2024. The interest rate for the term loan facility was a floating per annum interest rate equal to the greater of 3.75% above the Wall Street Journal Prime Rate and 9.25%. The interest rate for advances under the revolving facility was a floating per annum interest rate equal to the greater of the Wall Street Journal Prime Rate and 5.50% In August 2021, upon entering into the 2021 Credit Agreement, the Company paid an aggregate amount of $70,559 due under the 2019 Credit Agreement, including unpaid principal, accrued interest, the Final Payment and a prepayment fee, with proceeds from the 2021 Credit Agreement, and the 2019 Credit Agreement was terminated. Upon termination of the 2019 Credit Agreement, the Company recognized $1,883 as loss on the extinguishment of the loan for the year ended December 31, 2021. Master Lease Agreement In April 2017, the Company entered into the Master Lease Agreement (the “ML Agreement”) with Eastward Fund Management LLC. In March 2019, upon entering into the 2019 Credit Agreement, the Company paid an aggregate amount of $17,649 due under the ML Agreement with proceeds from the 2019 Credit Agreement, and the ML Agreement was terminated. Upon termination of the ML Agreement, the Company recognized $1,862 as loss on the extinguishment of the loan.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders' Equity	13. Stockholders’ Equity As of December 31, 2021, the issued shares of Class A common stock include 728,548 treasury shares that were reacquired in connection with the redemption of redeemable shares in March 2019. These redeemable shares were initially issued in connection with the acquisition of Nutech Medical, Inc. (“NuTech Medical”) in 2017 and included a put right. The holders of the shares exercised the right to put the shares back to the Company at an agreed-upon exercise price of $9.28 per share on March 24, 2019. Each share of Class A common stock entitles the holder to one vote on all matters submitted to the stockholders for a vote. Class A common stockholders are entitled to receive dividends, as may be declared by the Board of Directors. Through December 31, 2021, no cash dividends have been declared or paid. At December 31, 2021 and 2020, the Company has reserved the following shares of Class A common stock for future issuance: December 31, 2021 2020 Shares reserved for issuance for outstanding options 6,596,969 6,425,040 Shares reserved for issuance for outstanding restricted stock units 764,871 806,048 Shares reserved for issuance for future grants 5,644,691 6,832,649 Total shares of authorized common stock reserved for future issuance 13,006,531 14,063,737 Warrant Exchange and Warrant Exercise As of December 31, 2018, the Company had 4.3 million private warrants outstanding, 4.1 million of which were issued to Avista Capital Partners IV, L.P. and Avista Capital Partners IV (Offshore), L.P. in connection with the Avista Merger on December 10, 2018 (the “Private Warrants”), and 31.0 million public warrants outstanding that were issued in connection with the initial public offering of Avista Healthcare Public Acquisition Corp. on October 10, 2016 (the “Public Warrants”, together with the Private Warrants, the “Warrants”). In the third quarter of 2019, the Company executed a series of transactions related to its then outstanding 30,890,748 Public Warrants and 4,100,000 Private Warrants. The Company issued an aggregate of 2,845,280 shares of Class A common stock for 29,950,150 Public Warrants at an exchange rate of 0.095. The Company issued an aggregate of 80,451 shares of Class A common stock for the remaining Public Warrants at an exchange rate of 0.0855. The Company issued an aggregate of 389,501 shares of Class A common stock for the Private Warrants at an exchange rate of 0.095. As the fair value of the Warrants exchanged in the warrant exchange transactions immediately prior to the exchanges was less than the fair value of the Class A common stock issued, the Company recorded a non-cash deemed dividend of $ for the incremental fair value provided to the Warrant holders in the year ended December 31, 2019. The Company originally classified the Warrants as equity on its financial statements. As a result of the issuance of the SEC Statement in 2021, the Company reevaluated the historical accounting treatment of its Public Warrants and Private Warrants and determined that the Private Warrants should have been recorded at fair value as a liability in the Company’s consolidated balance sheet with changes to the fair value recorded to the consolidated statements of operations. See Note “2. Significant Accounting Policies” for detail. 2020 Underwritten Public Offering In November 2020, the Company additional paid-in capital received. 2019 Underwritten Public Offering In November 2019, the Company closed a public offering (the “2019 Underwritten Public Offering”) of 9,000,000 shares of the Company’s Class A common stock, par value $0.0001 per share, at a price per share to the public of $5.00, less underwriting discounts and commissions. In connection with this offering, the Company issued a total of 10,068,056 shares with gross proceeds of $50,340 and net proceeds of $46,831 after deducting underwriter discounts, payment of the fee to the Avista entities and other offering expenses in the aggregate amount of $3,510 which were recorded to additional paid-in

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Equity Incentive Plan Share-Based Compensation	14. Share-Based Compensation Stock Incentive Plans-the On November 28, 2018, the Board of Directors of the Company adopted, and on December 10, 2018, the Company’s stockholders approved, the Organogenesis 2018 Equity and Incentive Plan (the “2018 Plan”). The purposes of the 2018 Plan are to provide long-term incentives and rewards to the Company’s employees, officers, directors and other key persons (including consultants), to attract and retain persons with the requisite experience and ability, and to more closely align the interests of such employees, officers, directors and other key persons with the interests of the Company’s stockholders. The 2018 Plan authorizes the Company’s Board of Directors or a committee of not less than two independent directors (in either case, the “Administrator”) to grant the following types of awards: non-statutory As of December 31, 2021, a total of 9,198,996 shares of Class A common stock have been authorized to be issued under the 2018 Plan (subject to adjustment in the case of any stock dividend, stock split, reverse stock split, or similar change in capitalization of the Company). Stock Incentive Plans-the The Organogenesis 2003 Stock Incentive Plan (the “2003 Plan”), provides for the Company to issue restricted stock awards, or to grant incentive stock options or non-statutory non-statutory Effective as of the closing of the Avista Merger on December 10, 2018, no additional awards may be made under the 2003 Plan and as a result (i) any shares in respect of stock options that are expired or terminated under the 2003 Plan without having been fully exercised will not be available for future awards; (ii) any shares in respect of restricted stock that are forfeited to, or otherwise repurchased by the Company, will not be available for future awards; and (iii) any shares of Class A common stock that are tendered to the Company by a participant to exercise an award will not be available for future awards. Stock-Based Compensation Expense Stock options awarded under the stock incentive plans expire 10 years after the grant date and typically vest over four During the years ended December 31, 2021, 2020, and 2019, the Company recorded stock-based compensation expense of $3,864, $1,661, and $936, respectively, within selling, general and administrative expenses on the consolidated statements of operations. Restricted Stock Units (RSUs) During the year ended December 31, 2021, the Company granted 310,692 time-based restricted stock units to its employees, executives and the Board of Directors. Each restricted stock unit represents the contingent right to receive one share of the Company’s Class A common stock. The fair value of the restricted stock units was based on the fair market value of the Company’s stock on the date of grant. The activity of restricted stock units is set forth below: Number Weighted Unvested at December 31, 2020 787,923 $ 3.81 Granted 310,692 14.29 Vested (248,305 ) 4.20 Canceled/Forfeited (85,439 ) 7.64 Unvested at December 31, 2021 764,871 $ 7.52 As of December 31, 2021, the total unrecognized compensation cost related to unvested restricted stock units expected to vest was $3,273 and the weighted average remaining recognition period for unvested awards was 2.72 years. Stock Options The stock options granted during the years ended December 31, 2021, and 2020 were 1,069,658 and 1,553,723, respectively. The assumptions that the Company used to determine the grant-date fair value of stock options granted during these periods were as follows, presented on a weighted-average basis: Year Ended 2021 2020 Risk-free interest rate 0.83 % 0.46 % Expected term (in years) 6.22 6.22 Expected volatility 39.31 % 37.42 % Expected dividend yield 0.0 % 0.0 % Exercise price $ 13.57 $ 4.04 Underlying stock price $ 13.57 $ 3.37 These assumptions resulted in an estimated weighted-average grant-date fair value per share of stock options granted during the years ended December 31, 2021 and 2020 of $5.32 and $1.05, respectively. The following table summarizes the Company’s stock option activity since December 31, 2020: Number of Weighted Weighted Aggregate (in years) Outstanding as of December 31, 2020 6,615,223 $ 2.32 5.22 34,438 Granted 1,069,658 13.57 Exercised (955,736 ) 2.29 10,121 Canceled / forfeited (132,176 ) 4.67 Outstanding as of December 31, 2021 6,596,969 4.10 5.20 38,524 Options exercisable as of December 31, 2021 4,342,519 1.80 3.47 32,292 Options vested or expected to vest as of December 31, 2021 6,216,308 $ 3.79 4.98 37,618 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s Class A common stock for those stock options that have exercise prices lower than the fair value of the Company’s Class A common stock. The total fair value of options vested during the years ended December 31, 2021 and 2020 was $813 and $678, respectively. As of December 31, 2021, the total unrecognized stock compensation expense was $3,998 and was expected to be recognized over a weighted-average period of 2.92 years. Between 2010 and 2013, a former executive to o (see Note “19. Related Parties Transactions”). The repayments were treated as the exercise price for the 195,278 shares of the options and were included in the consolidated statement of stockholders’ equity. As of December 31, 2021, the partial recourse notes were paid off and all of the 675,990 shares used to secure the notes were considered outstanding f or accounting purposes.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes The components of the income tax expense (benefit) consisted of the following for the years ended December 31, 2021, 2020, and 2019: Year Ended December 31, 2021 2020 2019 Income tax expense (benefit): Current tax expense (benefit) Federal $ — $ (106 ) $ (105 ) State 899 505 116 Foreign (39 ) 19 28 Total current tax expense 860 418 39 Deferred tax expense (benefit) Federal (30,506 ) 109 105 State (1,470 ) — — Foreign — 3 6 Total deferred tax expense (31,976 ) 112 111 Total income tax expense (benefit) $ (31,116 ) $ 530 $ 150 On a periodic basis, the Company reassess the valuation allowance on its deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the fourth quarter of fiscal year 2021, the Company assessed the valuation allowance and considered positive evidence, including significant cumulative consolidated income over the three years ended December 31, 2021, revenue growth and expectations of future profitability, and negative evidence, including the impact of a negative change in the economic climate, significant risks and uncertainties in the business and restrictions on tax loss utilization in certain state jurisdictions. After assessing both the positive evidence and the negative evidence, the Company determined it was more likely than not that its deferred tax assets would be realized in the future and released the valuation allowance on its net deferred tax assets as of December 31, 2021, resulting in a benefit from income taxes of $48,252. As of December 31, 2021, the Company had available for the reduction of future years’ federal taxable income, net operating loss carry-forwards of approximately $103,619. Of these carry-forwards, $45,138 will expire from the year ended December 31, 2021 through 2037 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2021 and 2020 are as follows: December 31, 2021 2020 Net operating loss carryforwards Federal $ 21,760 $ 31,783 State 1,612 3,342 Foreign 16 18 Other 7,556 5,829 163j interest — 4,979 Stock-based compensation 676 357 Finance leases 632 2,991 Operating leases 12,918 — Fixed assets 2,748 2,589 Net deferred tax assets before valuation allowance 47,918 51,888 Valuation allowance — (48,252 ) ROU assets (12,273 — Intangibles (3,651 ) (3,618 ) Net deferred tax assets $ 31,994 $ 18 The Company’s subsidiary in Switzerland is carrying a deferred tax asset of approximately $16 relating to a net operating loss carryover that is expected to be benefited in the next couple of years. The Company has not recorded withholding taxes on the undistributed earnings of its Swiss subsidiary because it is the Company’s intent to reinvest such earnings indefinitely. Ownership changes, as defined in the Internal Revenue Code, may limit the amount of net operating losses and research and development tax credit carryforwards that can be utilized annually to offset future taxable income. Subsequent ownership changes could further affect the limitation in future years. The Company completed an analysis in 2021 and determined that it had not experienced an ownership change during the periods 2001 through 2021. The differences between income taxes expected at the U.S. federal statutory income tax rate of 21% and the reported consolidated income tax benefit (expense) are summarized as follows: December 31, 2021 2020 2019 U.S. federal statutory income tax rate 21.0 % 21.0 % 21.0 % Federal valuation allowance (70.6 )% (28.9 )% (17.6 )% State valuation allowance (9.1 )% (4.8 )% (3.9 )% State and local income taxes 6.8 % 6.2 % 3.5 % Nondeductible expenses 0.8 % 6.0 % (1.4 )% Uncertain tax position reserves 0.9 % 0.4 % (0.1 )% Research and development credits 0.9 % 3.0 % (1.9 )% Effective income tax rate (49.3 )% 2.9 % (0.4 )% The Company recognizes the tax benefit from an uncertain tax position only if it is more-likely-than-not that The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The amount of unrecognized tax benefits is A tabular roll forward of the Company’s uncertainties in its income tax provision liability is presented below: Year Ended December 31, 2021 2020 2019 Gross balance at beginning of year $ 2,123 $ 2,618 $ 3,286 Additions based on tax positions related to the current period 153 111 133 Reductions for tax positions of prior years (664 ) (606 ) (801 ) Gross balance at end of year $ 1,612 $ 2,123 $ 2,618 The Company files income tax returns in the U.S. federal and state jurisdictions and Switzerland. With limited exceptions, the Company is no longer subject to federal, state, local or foreign examinations for years prior to December 31, 2017. However, carryforward attributes that were generated prior to December 31, 2017 may still be adjusted upon examination by state or local tax authorities if they either have been or will be used in a future period. The Company recognizes interest and penalty-related expenses in tax expenses. There was $330 and $317 of interest recorded for uncertain tax positions for the years ended December 31, 2021 and 2020, respectively, which was classified in accrued expenses in the consolidated balance sheets. These amounts are not reflected in the reconciliation above.

Net Income (Loss) Per Share (EP

Net Income (Loss) Per Share (EPS)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	16. Net Income (Loss) Per Share (EPS) Basic EPS is calculated by dividing net income (loss) by the weighted-average number of shares outstanding during the period. Diluted EPS is calculated by dividing net income (loss) by the weighted-average number of shares outstanding plus the dilutive effect, if any, of outstanding equity awards using the treasury stock method which includes consideration of unrecognized compensation expenses as additional proceeds. A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net income (loss) attributable to the Class A common stockholders is as follows: Year Ended December 31, 2021 2020 2019 Numerator: Net Income (loss) $ 94,902 $ 17,234 $ (38,709 ) Less: Non-cash — — 568 Net Income (loss) attributable to common shareholders $ 94,902 $ 17,234 $ (39,277 ) Denominator: Weighted average common shares outstanding—basic 128,331,022 107,737,936 92,840,401 Dilutive effect of restricted stock units 469,123 135,932 — Dilutive effect of options 4,862,514 3,486,963 — Weighted-average common shares outstanding—diluted 133,662,659 111,360,831 92,840,401 Earnings (loss) per share—basic $ 0.74 $ 0.16 $ (0.42 ) Earnings (loss) per share—diluted $ 0.71 $ 0.15 $ (0.42 ) For the year ended December 31, 2021 and 2020, outstanding stock-based awards of 994,168 and 1,792,085 were excluded from the diluted EPS calculation as they are anti-dilutive. For the year ended December 31, 2019, the Company had a net loss. As such, 7,179,636 shares of potentially dilutive securities have been excluded from the computation of diluted net loss per share as these securities have anti-dilutive effects and including them would reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to Class A common stockholders was the same for this period.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	17. Leases As of December 31, 2021 and 2020, the Company’s contracts that contained a lease consisted primarily of real estate, equipment and vehicle leases. The Company leases real estate for office, lab, warehouse and production space under noncancelable operating and finance leases that expire at various dates through 2035, subject to the Company’s options to terminate or renew certain leases for an additional five The Company leases vehicles under operating leases for certain employees and has fleet services agreements for service on these vehicles. The minimum lease term for each newly leased vehicle is 367 days with renewal options. The Company may terminate the vehicle lease after the minimum lease term upon thirty days’ prior notice. The Company also leases other equipment under noncancelable operating and finance leases that expire at various dates through 2025. The Company determines if an arrangement is a lease at lease inception. The options to extend or terminate a lease are included in the lease terms when it is reasonably certain that the Company will exercise the options. Operating leases are included in operating lease right-of-use assets lease right-of-use assets Right-of-use assets leases. Right-of-use assets and lease liabilities are recognized based on the present value of the fixed lease payments over the lease term at the commencement date. The right-of-use assets The Company records rent expense for its operating leases on a straight-line basis from the lease commencement date until the end of the lease term. The Company records finance lease cost as a combination of the depreciation expense for the right-of-use assets initial right-of-use assets In March initial lease term was ten years from the rent commencement date and included an option for an early extension term of five years which was exercisable during the first two years after the rent commencement date. The Company exercised the option to extend the lease for additional five years in December 2021. In addition to the early extension term, the lease provides the Company with an option to extend the lease term for a period of ten years, if exercised, at rental rates equal to the then fair market value. Annual lease payments during the first year were $1,052 with increases of $44 each year during the initial ten-year lease In August 2020, the Company entered into a lease for approximately 23,000 square feet in San Diego, California for office and laboratory use. The lease commenced on April 1, 2021. The initial lease term is ten years from the lease commencement date, with an option to extend the term for a period of five years. Annual lease payments during the first year were $1,562 with a 3% increase each year during the lease term. A security deposit of $237 is required throughout the term of the lease. On January 1, 2013, the Company entered into finance lease arrangements with 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC and 275 Dan Road SPE, LLC for office and laboratory space in Canton, Massachusetts. 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC and 275 Dan Road SPE, LLC are related parties as the owners of these entities are also stockholders of the Company. Other than the lease with 275 Dan Road SPE, LLC which was terminated in August 2021 as discussed below, the remaining three leases were set to terminate on December 31, 2022 and each contained a renewal option for a five-year period with the rental rate at the greater of (i) rent for the last year of the prior term, or (ii) the then fair market value. The Company exercised the option to extend the leases for additional five years in November 2021. These leases were reclassified from finance leases to operating leases upon the Company’s reassessment of the lease classification according to ASC 842-10-25-1 Lease Classification. lease right-of-use assets As of December 31, 2020, the Company owed an aggregate of $10,336 of accrued but unpaid lease obligations under the aforementioned leases. Effective April 1, 2019, the Company agreed to accrue interest on the accrued but unpaid lease obligations at an interest rate equal to the rate charged in the 2019 Credit Agreement. These accrued but unpaid lease obligations as well as the accrued interest on these obligations were subordinated to the 2019 Credit Agreement. With the termination of the 2019 Credit Agreement and the execution of the 2021 Credit Agreement (see Note “12. Long-Term Debt Obligations”) in August 2021, these obligations are no longer subordinated to the Company’s existing loans. In August 2021, the Company purchased the building (the “275 Dan Road Building”) under the lease with 275 Dan Road SPE, LLC for $6,013 and the lease was terminated. The Company recorded an asset of $4,943 to buildings within fixed asset, net in accordance with ASC 842-20-40-2 Purchase of the Underlying Asset The accrued but unpaid lease obligations as well as the related interest accruals are shown below. The decrease of the interest portion of rent in arrears was due to the payment made by the Company in connection with the purchase of the 275 Dan Road Building as mentioned in the previous paragraph. December 31, 2021 2020 Principal portion of rent in arrears $ 7,246 $ 6,946 Interest portion of rent in arrears — 2,865 Unpaid operating and common area maintenance costs 558 525 Total accrued but unpaid lease obligations $ 7,804 $ 10,336 Accrued interest on accrued but unpaid lease obligations $ 1,938 $ 1,673 The components of lease cost were as follows: Classification Year Ended December 31, Finance lease Amortization of right-of-use COGS and SG&A $ 1,707 Interest on lease liabilities Interest Expense 980 Total Finance lease cost 2,687 Operating lease cost COGS, R&D, SG&A 7,066 Short-term lease cost COGS, R&D, SG&A 2,869 Variable lease cost COGS, R&D, SG&A 4,808 Total lease cost $ 17,430 Supplemental balance sheet information related to finance leases was as follows: December 31, 2021 January 1 2021 Property and equipment, gross $ 1,174 $ 22,989 Accumulated depreciation (961 ) (19,250 ) Property and equipment, ne $ 213 $ 3,739 Current portion of finance lease obligation $ 200 $ 3,619 Finance lease long-term obligations — 11,442 Total finance lease liabilities $ 200 $ 15,061 Supplemental cash flow information related to leases was as follows: Year Ended December 31, Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 7,276 Operating cash flows for finance leases $ 1,427 Financing cash flows for finance leases $ 2,630 Right-of-use assets obtained in exchange for lease obligations—upon adoption: Operating leases $ 13,525 Finance leases — Right-of-use assets obtained in exchange for lease obligations—post adoption: Operating leases $ 40,268 Finance leases — December 31, 2021 Weighted-average remaining lease term Finance leases 0.45 Operating leases 8.22 December 31, 2021 Weighted-average discount rate Finance leases 11.30 % Operating leases 4.51 % As of December 31, 2021, the maturities of lease liabilities were as follows: Operating Finance 2022 $ 14,032 $ 207 2023 8,100 — 2024 7,315 — 2025 7,526 — 2026 7,435 — Thereafter 25,936 — Total lease payments 70,344 207 Less: interest (11,666 ) (7 ) Total lease liabilities $ 58,678 $ 200 Under ASC 840, for the years ended December 31, 2020 and 2019, t

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure	18. Commitments and Contingencies Royalties The Company entered into a license agreement with a university for cer t In October 2017, the Company entered into a license agreement with a third party. Under the license agreement, the Company is required to pay royalties based on a percentage of net sales of the licensed product that occur, after December 31, 2017, through the expiration of the underlying patent in October 2026, subject to minimum royalty payment provisions. The Company recorded royalty expense of $5,929, $4,370, and $3,778 during the years ended December 31, 2021, 2020, and 2019, respectively, within selling, general and administrative expenses on the consolidated statements of operations. As part of the NuTech Medical acquisition, the Company inherited certain product development and consulting agreements for ongoing consulting services and royalty payments based on a percentage of net sales on certain products over a period of 15 years from the execution of the agreements. These product development and consulting agreements were canceled in January 2020 for total consideration of $1,950 which was paid on February 14 , 2020. The $1,950 cancellation fee was recorded within selling, general and administrative expenses on the consolidated statement of operations for the year ended December 31, 2020. Legal Matters In conducting its activities, the Company, from time to time, is subject to various claims and also has claims against others. In management’s opinion, the ultimate resolution of such claims would not have a material effect on the financial position, operating results or cash flows of the Company. The Company accrues for these claims when amounts due are probable and estimable. The Company accrued $150 as of December 31, 2021 and 2020 in relation to certain pending lawsuits. The purchase price for NuTech Medical acquired in 2017 included $7,500 deferred acquisition consideration of which the Company paid $2,500 in 2017. The remaining $5,000 of deferred acquisition consideration plus accrued interest owed to the sellers of NuTech Medical was previously in dispute. In February 2020, the Company entered into a settlement agreement with the sellers of NuTech Medical and settled the dispute for $4,000 of which, $2,000 was paid immediately on February 24, 2020 and the remaining $2,000 was paid in four quarterly installments of $500 each. As of March 31, 2021, the entire settlement was paid off. In addition, the Company assumed from the sellers of NuTech Medical the payment responsibilities related to a legacy lawsuit existing at the acquisition date of NuTech Medical. The assumed legacy lawsuit was settled in October 2020. In connection with the settlement of the deferred acquisition consideration dispute and the legacy lawsuit, the Company recorded a gain of $2,246 for the year ended December 31, 2020. The gain was included as a component of other expense, net, on the consolidated statement of operations.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	19. Related Parties Transactions Lease obligations to affiliates, including accrued but unpaid lease obligations, and purchase of an asset under a finance lease with an affiliate are further described in Note “17. Leases”. During 2010, the Company’s Board of Directors approved a loan program that permitted the Company to make loans to three executives of the Company (the “Employer Loans”) to (i) provide them with liquidity (“Liquidity Loans”) and (ii) fund the exercise of vested stock options (“Option Loans”). Two of the executives left the Company in 2014. The Employer Loans matured with all principal and accrued interest due on the tenth anniversary of the issuance date of each subject loan. Interest on the Employer Loans was at various rates ranging from 2.30%—3.86% per annum, compounded annually. The Employer Loans were secured by shares of the Company’s Class A common stock held by the former executives. With respect to the Liquidity Loans, the Company had no personal recourse against the borrowers beyond the pledged shares. As of December 31, 2020, Liquidity Loans and Option Loans to one former executive were outstanding with an aggregate principal balance of $100 and $334, respectively. During the three months ended March 31, 2021, this former executive paid off the outstanding principal balance of his Employer Loans and the related interest receivable. As a result, the Company recorded $179 as a recovery of the previously reserved related party receivables within selling, general and administrative expenses on the consolidated statement of operations for the year ended December 31, 2021. The $334 of the repaid principal balance of the Option Loans was recorded to equity. See Note “14. Share-Based Compensation”.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee Benefit Plan	20. Employee Benefit Plan The Company maintains a 401(k) Savings Plan (the “Plan”) for the U.S. employees. Under the Plan, eligible employees may contribute, subject to statutory limitations, a percentage of their salary to the Plan. Contributions made by the Company are made at the discretion of the Board of Directors and vest immediately. During the years ended December 31, 2021, 2020, and 2019, the Company made employer contributions of $3,092, $2,731, and $2,290, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events The Company has performed an evaluation of subsequent events through the time of filing this Annual Report on Form 10-K In the first quarter of 202 2 shares of restricted stock units were granted to our Board of Directors and executives. The majority of these options and restricted stock units will vest over

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Revision to Previously Issued Financial Statements	Revision to Previously Issued Financial Statements Private Warrant Reclassification On April 12, 2021, the Staff of the SEC issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). In the SEC Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s financial statements as opposed to equity. As of December 31, 2018, the Company had 4.1 million private warrants outstanding, which were issued to Avista Capital Partners IV, L.P. and Avista Capital Partners IV (Offshore), L.P. in connection with the Avista Merger on December 10, 2018 (the “Private Warrants”), and 31.0 million public warrants outstanding that were issued in connection with the initial public offering of Avista Healthcare Public Acquisition Corp. on October 10, 2016 (the “Public Warrants”, together with the Private Warrants, the “Warrants”). The Company originally classified the Warrants as equity on its financial statements. In 2019, the outstanding Warrants were exchanged for 3.3 million shares of the Company’s Class A common stock (see Note “13. Stockholders’ Equity”. There were no Warrants outstanding as of December 31, 2019. As a result of the SEC Statement, the Company reevaluated the historical accounting treatment of its Public Warrants and Private Warrants and determined that the Private Warrants should have been recorded at fair value as a liability in the Company’s consolidated balance sheet with changes to the fair value recorded to the consolidated statements of operations. The Company assessed the materiality of this error on prior period financial statements in accordance with the SEC Staff Accounting Bulletin Number 99, Materiality, and In August 2021, the Company identified an error in its accounting treatment for two assets recorded as finance leases. The Company did not record amortization expenses for these assets since the lease commencement date. This error resulted in an overstatement of property and equipment, net, and an understatement of accumulated deficit, and selling, general and administrative expenses in the financial statements included in the Company’s quarterly reports on Form 10-Q 10-K ASC 250-10, To correct the misstatements above, the Company revised its previously issued financial statements as follows: As of December 31, 2020 CONSOLIDATED BALANCE SHEETS As Previously Adjustments As Revised Property and equipment, net $ 60,068 $ (4,276 ) $ 55,792 Total assets $ 294,494 $ (4,276 ) $ 290,218 Additional paid-in $ 299,129 $ (2,299 ) $ 296,830 Accumulated deficit $ (153,058 ) $ (1,977 ) $ (155,035 ) Total stockholders’ equity $ 146,084 $ (4,276 ) $ 141,808 Total liabilities and stockholders’ equity $ 294,494 $ (4,276 ) $ 290,218 For the Year Ended December 31, 2020 For the Year Ended December 31, 2019 CONSOLIDATED STATEMENTS OF OPERATIONS As Adjustments As Revised As Adjustments As Revised Selling, general and administrative $ 203,478 $ 715 $ 204,193 $ 199,693 $ 395 $ 200,088 Total operating expenses $ 223,564 $ 715 $ 224,279 $ 214,492 $ 395 $ 214,887 Income from operations $ 27,415 $ (715 ) $ 26,700 $ (29,459 ) $ (395 ) $ (29,854 ) Change in fair value of warrant liability $ — $ 2,140 $ 2,140 Total other expense, net $ (10,845 ) $ 2,140 $ (8,705 ) Net income (loss) before income taxes $ 18,479 $ (715 ) $ 17,764 $ (40,304 ) $ 1,745 $ (38,559 ) Net income (loss) $ (40,454 ) $ 1,745 $ (38,709 ) Non-cash deemed $ (645 ) $ 77 $ (568 ) Net income (loss) attributed to common shareholders $ 17,949 $ (715 ) $ 17,234 $ (41,099 ) $ 1,822 $ (39,277 ) Net income (loss), per share: Basic $ 0.17 $ 0.16 $ (0.44 ) $ (0.42 ) Diluted $ 0.16 $ 0.15 $ (0.44 ) $ (0.42 ) For the Year Ended December 31, 2020 CONSOLIDATED STATEMENTS OF CASH FLOWS As Previously Adjustments As Revised Net loss $ 17,949 $ (715 ) $ 17,234 Depreciation $ 3,723 $ 715 $ 4,438 Recovery of certain notes receivable from related parties $ (1,516 ) $ 1,516 $ — Prepaid expenses and other current assets $ (971 ) $ 616 $ (355 ) Accounts payable $ (635 ) $ (3,467 ) $ (4,102 ) Net cash provided by (used in) operating activities $ 6,801 $ (1,335 ) $ 5,466 Purchases of property and equipment $ (21,145 ) $ 3,467 $ (17,678 ) Proceeds from the repayment of notes receivable from related parties $ 2,132 $ (2,132 ) $ — Net cash used in investing activities $ (24,833 ) $ 1,335 $ (23,498 ) For the Year Ended December 31, 2019 CONSOLIDATED STATEMENTS OF CASH FLOWS As Previously Adjustments As Revised Net loss $ (40,454 ) $ 1,745 $ (38,709 ) Depreciation $ 3,388 $ 395 $ 3,783 Change in fair value of warrant liability $ — $ (2,140 ) $ (2,140 )
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported results of operations during the reporting periods. In preparing the consolidated financial statements, the estimates and assumptions that management consider to be significant and that present the greatest amount of uncertainty include revenue recognition; sales returns and credit losses; inventory reserve; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite lived assets (including intangible assets), assessing impairment of goodwill; valuation of assets and liabilities that use unobservable inputs, and the valuation and recognition of stock-based compensation. Actual results and outcomes may differ significantly from those estimates and assumptions.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts and results of operations of Organogenesis Holdings Inc., and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Segment Reporting	Segment Reporting Operating segments are defined as components of an enterprise about which discrete financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance for the organization. The Company’s chief operating decision maker is the Chief Executive Officer. The Company’s chief operating decision maker reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. Accordingly, the Company has determined that it has a single operating segment—regenerative medicine. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s portfolio includes regenerative medicine products in various stages, ranging from preclinical to late stage development, and commercialized advanced wound care and surgical and sports medicine products which support healing across a wide variety of wound types at many different types of facilities.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company primarily maintains its cash in bank deposit accounts in the United States which, at times, may exceed the federally insured limits. The Company has not experienced losses in such accounts and believes it is not exposed to significant credit risk on cash. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Restricted Cash	Restricted Cash The Company had restricted cash of $599 and $412 as of December 31, 2021 and 2020, respectively. Restricted cash represents employee deposits in connection with the Company’s health benefit plan.
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable are stated at invoice value less estimated allowances for doubtful accounts. The Company continually monitors customer payments and maintains a reserve for estimated losses resulting from its customers’ inability to make required payments. The Company considers factors when estimating the allowance for doubtful accounts such as historical experience, credit quality, age of the accounts receivable balances, geography-related risks and economic conditions that may affect a customer’s ability to pay. In cases where there are circumstances that may impair a specific customer’s ability to meet its financial obligations, a specific allowance is recorded against amounts due, thereby reducing the net recognized receivable to the amount reasonably believed to be collectible. Accounts receivables are written off when deemed uncollectible. Recoveries of accounts receivables previously written off are recorded when received.
Inventories	Inventories Inventories are stated at the lower of cost (determined under the first-in first-out The Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value based upon management’s assumptions of future material usage, yields and obsolescence, which are a result of future demand and market conditions and the effective life of certain inventory items. The Company also tests other components of its inventory for future growth projections. The Company determines the average yield of the component and compares it to projected revenue to ensure it is properly reserved.
Property and Equipment, Net	Property and Equipment, Net Property and equipment are recorded at cost and depreciated over the estimated useful lives of the respective assets on a straight-line basis. As of December 31, 2021 and 2020, the Company’s property and equipment consisted of leasehold improvements, building, furniture and computers, and equipment. Property and equipment’s estimated useful lives are as follows: Leasehold improvements Lesser of the life of the lease or the economic life of the asset Building 30 years Furniture and computers 3-5 years Equipment 5-10 years Upon retirement or sale, the cost of assets disposed of, and the related accumulated deprecia tion
Goodwill	Goodwill Goodwill represents the excess of the purchase price of an acquired business over the fair value of the identifiable assets acquired and liabilities assumed. Goodwill is not amortized, but is tested for impairment at least annually (as of December 31), or more frequently if events or circumstances indicate the carrying value may no longer be recoverable and that an impairment loss may have occurred. Circumstances that could trigger an impairment test include, but are not limited to, a ++significant adverse change in the business climate or legal factors, an adverse action or assessment by a regulator, or unanticipated competition. The Company operates as one segment, which is considered to be the sole reporting unit, and therefore goodwill is tested for impairment at the consolidated level. In accordance with ASC Topic 350, Intangibles—Goodwill and Other, There was no impairment of goodwill recorded during the years ended December 31, 2021, 2020, or 2019.
Intangible Assets Subject to Amortization	Intangible Assets Subject to Amortization Intangible assets include intellectual property either owned by the Company or for which the Company has a license. Intangible assets acquired in a business combination are recognized at fair value using generally accepted valuation methods deemed appropriate for the type of intangible asset acquired. Intangible assets are reported net of accumulated amortization, separately from goodwill. Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets include developed technology and patents, trade names, trademarks, customer relationships and non-compete Trade names and trademarks 1-12 Developed technology 6-12 Customer relationships 10 years Non-compete 5 years
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment and intangible assets. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include, but not limited to, significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. When such an event occurs, the Company determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the related asset group’s carrying value. If an asset is determined to be impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not record any impairment of long-lived assets during the years ended December 31, 2021, 2020, or 2019.
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process The Company did not record any deferred offering costs in the consolidated balance sheets as of December 31, 2021 and 2020. During the year ended December 31, 2020 and 2019, the Company recorded $4,647 and $3,510 of equity issuance costs to additional paid-in
Revenue Recognition	Revenue Recognition Product Revenue The Company generates revenue through the sale of Advanced Wound Care and Surgical & Sports Medicine products. There is a single performance obligation in all of the Company’s contracts, which is the Company’s promise to transfer the Company’s product to customers based on specific payment and shipping terms in the arrangement. The entire transaction price is allocated to this single performance obligation. Product revenue is recognized when a customer obtains control of the Company’s product which occurs at a point in time and may be upon shipment, procedure date, or delivery, based on the terms of the contract. Reserves for Variable Consideration Revenues from product sales are recorded net of reserves for variable consideration which includes but is not limited to product return, discounts, rebates and group purchasing organization (“GPO”) fees that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed by its customers on the related sales and are recorded as a reduction of accounts receivable or an establishment of a liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract and is included in the net sales price to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately paid may differ from the Company’s estimates. If actual results vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Product Returns Consistent with industry practice, the Company generally offers customers a limited right of return for product purchased. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return reserves using its historical return rates as well as factors that it becomes aware of that it believes could significantly impact its expected returns, including product recalls, pricing changes, or change in reimbursement rates. The Company does not record an asset for the returned product as the product is discarded upon receipt. Rebates and Allowances The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts, resulting in a reduction of revenue and the establishment of a liability that is included in accrued expenses in the accompanying consolidated balance sheets in the period the related product revenue is recognized. GPO Fees The Company pays fees to GPOs for administrative services that the GPOs perform in connection with the purchases of the product by the GPO members. These fees are based on a contractually-determined percentage of the Company’s applicable sales. The Company classifies these GPO fees as a reduction of revenue based on the substance of the relationship of all parties involved in the transaction. For the years ended December 31, 2021, 2020, and 2019, the Company recorded GPO fees of $2,963, $3,572, and $3,096, respectively, as a direct reduction of revenue. Other Revenue Policies Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Applying the practical expedient in paragraph ASC 606-10-32-18, Applying the practical expedient in ASC 340-40-25-4, Applying the practical expedient in ASC 606-10-25-18B, Disaggregation of Revenue The following table sets forth revenue by product category: Year Ended December 31, 2021 2020 2019 Advanced Wound Care revenue $ 430,839 $ 294,624 $ 220,744 Surgical and Sports Medicine revenue 37,220 43,674 40,237 Total revenue $ 468,059 $ 338,298 $ 260,981 For all periods presented, net revenue generated outside the United States represented less than 1% of total net revenue.​​​​​​​
Stock-Based Compensation	Stock-Based Compensation The Company measures stock-based awards granted based on the fair value of the awards on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Generally, the Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has not issued any stock-based awards with performance-based vesting conditions. The Company recognizes stock-based compensation expense within selling, general and administrative expenses in the consolidated statement of operations for all share-based payments based upon the estimated grant-date fair value for the awards expected to ultimately vest. The fair value of each restricted stock unit grant is based on the fair market value of the Company’s stock on the date of grant. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company has been a public company for a short period of time, has limited public float and lacks company-specific historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on its Class A common stock and does not expect to pay any cash dividends in the foreseeable future.
Advertising	Advertising Advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of operations. Advertising costs were approximately $5,522, $2,722, and $1,059 for the years ended December 31, 2021, 2020, and 2019, respectively.
Research and Development Costs	Research and Development Costs Research and development expenses include personnel costs for the Company’s research and development personnel, expenses related to improvements to manufacturing processes, enhancements to the Company’s currently available products, and additional investments in the product and platform development pipeline. Research and development expenses also include expenses for clinical trials. The Company expenses research and development costs as incurred.
Foreign Currency	Foreign Currency The Company’s functional currency, including the Company’s Swiss subsidiary, Organogenesis GmbH, is the U.S. dollar. Foreign currency gains and losses resulting from re-measurement of as non-operating income
Valuation of Contingent Purchase Earnout	Valuation of Contingent Purchase Earnout In connection with the acquisition of CPN Biosciences, LLC (“CPN”), the Company recognized a non-current liability for the fair value of the contingent consideration (the “Earnout”) at the time of the acquisition in 2020. The Earnout liability is classified as a Level 3 measurement for which fair value is derived from inputs that are unobservable and significant to the overall fair value measurement. The fair value of such Earnout liability is estimated using a Monte Carlo simulation model that utilizes key assumptions including forecasted revenues and volatilities of the underlying financial metrics during the Earnout period. The Company assesses the fair value of the Earnout liability at each reporting period. Any subsequent changes in the estimated fair value of the liability are reflected in selling, general and administrative expenses until the liability is settled.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statement and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company quarterly assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. In determining whether a valuation allowance for deferred tax assets is necessary, we analyze both positive and negative evidence related to the realization of deferred tax assets , including projected future taxable income, recent financial results and estimates of future reversals of deferred tax assets and liabilities. In the fourth quarter of 2021, we determined it was more likely than not that our deferred tax assets would be realized in the future and released the valuation allowance on our net deferred tax assets as of December 31, 2021, resulting in a benefit in income taxes. See Note “15. Income Taxes.” The Company accounts for uncertain income tax positions recognized in the consolidated financial statements by applying a two-step more-likely-than-not
Fair Value of Financial Instruments	Fair Value of Financial Instruments Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values of accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Earnout liability was carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above (see Note “4. Fair Value Measurement of Financial Instruments”). The carrying values of outstanding borrowings under the Company’s debt arrangements “12. Long-Term Debt Obligations”) approximate their fair values as determined based on a discounted cash flow model, which represents a Level 3 measurement.​​​​​​​
Net Income (Loss) per Share	Net Income (Loss) per Share The Company determines net income (loss) per share in accordance with the authoritative guidance in ASC Topic 260, Earnings Per Share
Emerging Growth Company	Emerging Growth Company Before December 31, 2021, the Company was an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company elected to use the extended transition period for complying with new or revised accounting standards (such as ASU 2016-02, Leases
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-02 2016-02”), Leases Topic 842), right-of-use Leases months or less. The Company also elected to account for lease components and the associated non-lease right-of-use right-of-use de-recognition In December 2019, the FASB issued ASU No. 2019-12, Income Taxes—Simplifying the Accounting for Income Taxes 2019-12
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Subsequent ASU 2016-13, the ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging and Topic 825 Financial Instruments ASU 2019-05, Financial Instruments—Credit Losses (Topic 326)—Targeted Transition Relief ASU 2019-11, Codification Improvements to Topic 326 Financial Instruments—Credit Losses ASU 2016-13 and ASU 2016-13 and ASU 2016-13 In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting 2020-04”). 2020-04 No. 2021-01, Reference Rate Reform (Topic 848): Scope 2021-01”), 2020-04 2021-01 through December 31, 2022. The Company’s debt agreement that utilizes LIBOR has conventional LIBOR replacement language. Since the debt agreement has not discontinued the use of LIBOR, this ASU is not yet effective for the Company. To the extent the interest rate changes to the rate specified in the debt agreement , the Company will utilize the relief in this ASU. The Company evaluated the effects of adopting the provisions of ASU 2020-04 2021-01

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule Of Revision Of Previously Issued Financial Statements To Correct The Misstatements	To correct the misstatements above, the Company revised its previously issued financial statements as follows: As of December 31, 2020 CONSOLIDATED BALANCE SHEETS As Previously Adjustments As Revised Property and equipment, net $ 60,068 $ (4,276 ) $ 55,792 Total assets $ 294,494 $ (4,276 ) $ 290,218 Additional paid-in $ 299,129 $ (2,299 ) $ 296,830 Accumulated deficit $ (153,058 ) $ (1,977 ) $ (155,035 ) Total stockholders’ equity $ 146,084 $ (4,276 ) $ 141,808 Total liabilities and stockholders’ equity $ 294,494 $ (4,276 ) $ 290,218 For the Year Ended December 31, 2020 For the Year Ended December 31, 2019 CONSOLIDATED STATEMENTS OF OPERATIONS As Adjustments As Revised As Adjustments As Revised Selling, general and administrative $ 203,478 $ 715 $ 204,193 $ 199,693 $ 395 $ 200,088 Total operating expenses $ 223,564 $ 715 $ 224,279 $ 214,492 $ 395 $ 214,887 Income from operations $ 27,415 $ (715 ) $ 26,700 $ (29,459 ) $ (395 ) $ (29,854 ) Change in fair value of warrant liability $ — $ 2,140 $ 2,140 Total other expense, net $ (10,845 ) $ 2,140 $ (8,705 ) Net income (loss) before income taxes $ 18,479 $ (715 ) $ 17,764 $ (40,304 ) $ 1,745 $ (38,559 ) Net income (loss) $ (40,454 ) $ 1,745 $ (38,709 ) Non-cash deemed $ (645 ) $ 77 $ (568 ) Net income (loss) attributed to common shareholders $ 17,949 $ (715 ) $ 17,234 $ (41,099 ) $ 1,822 $ (39,277 ) Net income (loss), per share: Basic $ 0.17 $ 0.16 $ (0.44 ) $ (0.42 ) Diluted $ 0.16 $ 0.15 $ (0.44 ) $ (0.42 ) For the Year Ended December 31, 2020 CONSOLIDATED STATEMENTS OF CASH FLOWS As Previously Adjustments As Revised Net loss $ 17,949 $ (715 ) $ 17,234 Depreciation $ 3,723 $ 715 $ 4,438 Recovery of certain notes receivable from related parties $ (1,516 ) $ 1,516 $ — Prepaid expenses and other current assets $ (971 ) $ 616 $ (355 ) Accounts payable $ (635 ) $ (3,467 ) $ (4,102 ) Net cash provided by (used in) operating activities $ 6,801 $ (1,335 ) $ 5,466 Purchases of property and equipment $ (21,145 ) $ 3,467 $ (17,678 ) Proceeds from the repayment of notes receivable from related parties $ 2,132 $ (2,132 ) $ — Net cash used in investing activities $ (24,833 ) $ 1,335 $ (23,498 ) For the Year Ended December 31, 2019 CONSOLIDATED STATEMENTS OF CASH FLOWS As Previously Adjustments As Revised Net loss $ (40,454 ) $ 1,745 $ (38,709 ) Depreciation $ 3,388 $ 395 $ 3,783 Change in fair value of warrant liability $ — $ (2,140 ) $ (2,140 )
Summary of Estimated Useful Lives of Property Plant and Equipment	Leasehold improvements Lesser of the life of the lease or the economic life of the asset Building 30 years Furniture and computers 3-5 years Equipment 5-10 years
Schedule of Finite-Lived Intangible Assets	Amortization of intangible assets with finite lives is calculated on the straight-line or accelerated method based on the following estimated useful lives: Trade names and trademarks 1-12 Developed technology 6-12 Customer relationships 10 years Non-compete 5 years
Schedule of Revenue by Product Category	The following table sets forth revenue by product category: Year Ended December 31, 2021 2020 2019 Advanced Wound Care revenue $ 430,839 $ 294,624 $ 220,744 Surgical and Sports Medicine revenue 37,220 43,674 40,237 Total revenue $ 468,059 $ 338,298 $ 260,981

Fair Value Measurement of Fin_2

Fair Value Measurement of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value, by Balance Sheet Grouping	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2021 and 2020. Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Liabilities: Earnout liability $ — $ — $ — $ — $ — $ — $ — $ — Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Liabilities: Earnout liability $ — $ — $ 3,985 $ 3,985 $ — $ — $ 3,985 $ 3,985
Summary of Fair Value of Earnout liability	The following table provides a roll-forward of the fair value of the Company’s Earnout liability, for which fair value is determined using Level 3 inputs: Earnout Balance as of December 31, 2019 $ — Acquisition Date fair value 3,782 Change in fair value 203 Balance as of December 31, 2020 3,985 Change in fair value (3,985 ) Balance as of December 31, 2021 $ —
Fair Value Recognized As a Component of Other Expense	The Private Warrants were settled in the warrant exchange transactions in the third quarter of 2019, with a decrease of 2,140 in the fair value recognized as a component of other expense, net in the consolidated statements of operation for the year ended 2019. Warrant Balance as of December 31, 2019 $ 3,936 Change in fair value (2,140 ) Settled in warrant exchange transaction (1,796 ) Balance as of December 31, 2020 $ —

Accounts receivable, net (Table

Accounts receivable, net (Tables)	12 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Schedule of accounts receivable	Accounts receivable consisted of the following: December 31, 2021 2020 Accounts receivable $ 87,613 $ 59,473 Less—allowance for doubtful accounts (5,153 ) (2,669 ) $ 82,460 $ 56,804
Schedule of allowance for doubtful accounts	The Company’s allowance for doubtful accounts was comprised of the following: Balance as of December 31, 2019 $ 1,988 Additions 1,183 Write-offs (502 ) Balance as of December 31, 2020 $ 2,669 Additions 2,999 Write-offs (515 ) Balance as of December 31, 2021 $ 5,153

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories, net of related reserves, consisted of the following: December 31, 2021 2020 Raw materials $ 9,023 $ 10,075 Work in process 991 1,305 Finished goods 15,008 16,419 $ 25,022 $ 27,799

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following: December 31, 2021 2020 Subscriptions $ 2,745 $ 2,013 Conferences and marketing expenses 538 63 Deposits 1,216 1,438 Reimbursement of offering expenses — 1,009 Insurance 358 240 Other 112 172 $ 4,969 $ 4,935

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and equipment consisted of the following: December 31, 2021 2020 Leasehold improvements $ 30,531 $ 39,574 Building 4,943 — Furniture, computers and equipment 53,959 48,236 89,433 87,810 Accumulated depreciation and amortization (57,729 ) (73,797 ) Construction in progress 47,456 41,779 $ 79,160 $ 55,792

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Identifiable intangible assets consisted of the following as of December 31, 2021: Original Accumulated Amortization Net Book Value Developed technology $ 32,620 $ (17,709 ) $ 14,911 Trade names and trademarks 2,080 (1,183 ) 897 Customer relationship 10,690 (1,381 ) 9,309 Independent sales agency network 4,500 (4,500 — Patent 7,623 (7,623 — Non-compete 1,010 (454 ) 556 Total $ 58,523 $ (32,850 ) $ 25,673 Identifiable intangible assets consisted of the following as of December 31, 2020: Original Accumulated Net Book Value Developed technology $ 32,620 $ (14,330 ) $ 18,290 Trade names and trademarks 2,080 (906 ) 1,174 Customer relationship 10,690 (312 ) 10,378 Independent sales agency network 4,500 (4,500 — Patent 7,623 (7,623 — Non-compete 1,010 (230 ) 780 Total $ 58,523 $ (27,901 ) $ 30,622
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated future annual amortization expense related to these intangible assets is as follows: 2022 $ 4,883 2023 4,918 2024 3,403 2025 3,323 2026 3,043 Thereafter 6,103 Total $ 25,673

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses and other current liabilities consisted of the following: December 31, 2021 2020 Personnel costs $ 26,865 $ 18,943 Royalties 3,458 2,971 Accrued but unpaid lease obligations and interest 3,963 — Other 2,303 2,059 $ 36,589 $ 23,973

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Summary of liability related to the restructuring activities	The following table provides a roll-forward of the restructuring liability. Employee Facility Liability balance as of December 31, 2019 $ — $ — Expenses 618 — Cash distributions — — Liability balance as of December 31, 2020 618 — Expenses 3,513 1,191 Cash distributions (1,614 ) (540 ) Liability balance as of December 31, 2021 $ 2,517 $ 651

Long-Term Debt Obligations (Tab

Long-Term Debt Obligations (Tables)	12 Months Ended
	Dec. 31, 2021
Long-term Debt, Unclassified [Abstract]
Schedule of long-term debt obligations	December 31, 2021 2020 Line of credit $ — $ 10,000 Term loan 74,062 60,000 Less debt discount and debt issuance cost (637 ) (290 ) Term loan, net of debt discount and debt issuance cost $ 73,425 $ 59,710
Schudle of future payments of term loan facility	Future payments of the 2021 Credit Agreement, as of December 31, 2021, are as follows for the calendar years ending December 31: 2022 $ 2,812 2023 4,687 2024 5,625 2025 6,563 2026 and beyond 54,375 Total $ 74,062

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule Of Common Stock Shares Reserved For Future Issuance	At December 31, 2021 and 2020, the Company has reserved the following shares of Class A common stock for future issuance: December 31, 2021 2020 Shares reserved for issuance for outstanding options 6,596,969 6,425,040 Shares reserved for issuance for outstanding restricted stock units 764,871 806,048 Shares reserved for issuance for future grants 5,644,691 6,832,649 Total shares of authorized common stock reserved for future issuance 13,006,531 14,063,737

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of Unvested Restricted Stock Units	The activity of restricted stock units is set forth below: Number Weighted Unvested at December 31, 2020 787,923 $ 3.81 Granted 310,692 14.29 Vested (248,305 ) 4.20 Canceled/Forfeited (85,439 ) 7.64 Unvested at December 31, 2021 764,871 $ 7.52
Schedule of Fair Value of Stock Options Granted to Employees and Directors	Year Ended 2021 2020 Risk-free interest rate 0.83 % 0.46 % Expected term (in years) 6.22 6.22 Expected volatility 39.31 % 37.42 % Expected dividend yield 0.0 % 0.0 % Exercise price $ 13.57 $ 4.04 Underlying stock price $ 13.57 $ 3.37
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity since December 31, 2020: Number of Weighted Weighted Aggregate (in years) Outstanding as of December 31, 2020 6,615,223 $ 2.32 5.22 34,438 Granted 1,069,658 13.57 Exercised (955,736 ) 2.29 10,121 Canceled / forfeited (132,176 ) 4.67 Outstanding as of December 31, 2021 6,596,969 4.10 5.20 38,524 Options exercisable as of December 31, 2021 4,342,519 1.80 3.47 32,292 Options vested or expected to vest as of December 31, 2021 6,216,308 $ 3.79 4.98 37,618

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The components of the income tax expense (benefit) consisted of the following for the years ended December 31, 2021, 2020, and 2019: Year Ended December 31, 2021 2020 2019 Income tax expense (benefit): Current tax expense (benefit) Federal $ — $ (106 ) $ (105 ) State 899 505 116 Foreign (39 ) 19 28 Total current tax expense 860 418 39 Deferred tax expense (benefit) Federal (30,506 ) 109 105 State (1,470 ) — — Foreign — 3 6 Total deferred tax expense (31,976 ) 112 111 Total income tax expense (benefit) $ (31,116 ) $ 530 $ 150
Component of Company's Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2021 and 2020 are as follows: December 31, 2021 2020 Net operating loss carryforwards Federal $ 21,760 $ 31,783 State 1,612 3,342 Foreign 16 18 Other 7,556 5,829 163j interest — 4,979 Stock-based compensation 676 357 Finance leases 632 2,991 Operating leases 12,918 — Fixed assets 2,748 2,589 Net deferred tax assets before valuation allowance 47,918 51,888 Valuation allowance — (48,252 ) ROU assets (12,273 — Intangibles (3,651 ) (3,618 ) Net deferred tax assets $ 31,994 $ 18
Schedule of Effective Income Tax Rate Reconciliation	The differences between income taxes expected at the U.S. federal statutory income tax rate of 21% and the reported consolidated income tax benefit (expense) are summarized as follows: December 31, 2021 2020 2019 U.S. federal statutory income tax rate 21.0 % 21.0 % 21.0 % Federal valuation allowance (70.6 )% (28.9 )% (17.6 )% State valuation allowance (9.1 )% (4.8 )% (3.9 )% State and local income taxes 6.8 % 6.2 % 3.5 % Nondeductible expenses 0.8 % 6.0 % (1.4 )% Uncertain tax position reserves 0.9 % 0.4 % (0.1 )% Research and development credits 0.9 % 3.0 % (1.9 )% Effective income tax rate (49.3 )% 2.9 % (0.4 )%
Schedule of Unrecognized Tax Benefits Roll Forward	A tabular roll forward of the Company’s uncertainties in its income tax provision liability is presented below: Year Ended December 31, 2021 2020 2019 Gross balance at beginning of year $ 2,123 $ 2,618 $ 3,286 Additions based on tax positions related to the current period 153 111 133 Reductions for tax positions of prior years (664 ) (606 ) (801 ) Gross balance at end of year $ 1,612 $ 2,123 $ 2,618

Net Income (Loss) Per Share (_2

Net Income (Loss) Per Share (EPS) (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net income (loss) attributable to the Class A common stockholders is as follows: Year Ended December 31, 2021 2020 2019 Numerator: Net Income (loss) $ 94,902 $ 17,234 $ (38,709 ) Less: Non-cash — — 568 Net Income (loss) attributable to common shareholders $ 94,902 $ 17,234 $ (39,277 ) Denominator: Weighted average common shares outstanding—basic 128,331,022 107,737,936 92,840,401 Dilutive effect of restricted stock units 469,123 135,932 — Dilutive effect of options 4,862,514 3,486,963 — Weighted-average common shares outstanding—diluted 133,662,659 111,360,831 92,840,401 Earnings (loss) per share—basic $ 0.74 $ 0.16 $ (0.42 ) Earnings (loss) per share—diluted $ 0.71 $ 0.15 $ (0.42 )

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of Lease Cost	The components of lease cost were as follows: Classification Year Ended December 31, Finance lease Amortization of right-of-use COGS and SG&A $ 1,707 Interest on lease liabilities Interest Expense 980 Total Finance lease cost 2,687 Operating lease cost COGS, R&D, SG&A 7,066 Short-term lease cost COGS, R&D, SG&A 2,869 Variable lease cost COGS, R&D, SG&A 4,808 Total lease cost $ 17,430
Summary of Balance Sheet Information Related To Finance Leases	Supplemental balance sheet information related to finance leases was as follows: December 31, 2021 January 1 2021 Property and equipment, gross $ 1,174 $ 22,989 Accumulated depreciation (961 ) (19,250 ) Property and equipment, ne $ 213 $ 3,739 Current portion of finance lease obligation $ 200 $ 3,619 Finance lease long-term obligations — 11,442 Total finance lease liabilities $ 200 $ 15,061
Schedule of Accrued but Unpaid Lease Obligations
Summary of Cash Flow Information Related To Leases	Supplemental cash flow information related to leases was as follows: Year Ended December 31, Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 7,276 Operating cash flows for finance leases $ 1,427 Financing cash flows for finance leases $ 2,630 Right-of-use assets obtained in exchange for lease obligations—upon adoption: Operating leases $ 13,525 Finance leases — Right-of-use assets obtained in exchange for lease obligations—post adoption: Operating leases $ 40,268 Finance leases — December 31, 2021 Weighted-average remaining lease term Finance leases 0.45 Operating leases 8.22 December 31, 2021 Weighted-average discount rate Finance leases 11.30 % Operating leases 4.51 %
Summary of Maturities of Lease Liabilities	As of December 31, 2021, the maturities of lease liabilities were as follows: Operating Finance 2022 $ 14,032 $ 207 2023 8,100 — 2024 7,315 — 2025 7,526 — 2026 7,435 — Thereafter 25,936 — Total lease payments 70,344 207 Less: interest (11,666 ) (7 ) Total lease liabilities $ 58,678 $ 200

Nature of the Business and Basi

Nature of the Business and Basis of Presentation - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021Segments
Business Acquisition [Line Items]
Number of Operating Segments	1
Number of Reportable Segments	1

Significant Accounting Polici_4

Significant Accounting Policies - Property, Plant and Equipment (Detail)	12 Months Ended
	Dec. 31, 2021
Leasehold improvements
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Lesser of the life of the lease or the economic life of the asset
Building
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	30 years
Furniture and computers | Minimum
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture and computers | Maximum
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Equipment | Minimum
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Equipment | Maximum
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Significant Accounting Polici_5

Significant Accounting Policies -Schedule of Finite-Lived Intangible Assets (Detail)	12 Months Ended
	Dec. 31, 2021
Trade names and trademarks | Minimum
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Trade names and trademarks | Maximum
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	12 years
Developed technology | Minimum
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	6 years
Developed technology | Maximum
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	12 years
Customer relationships
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Non-compete agreements
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years

Significant Accounting Polici_6

Significant Accounting Policies - Schedule of Revenue by Product Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Total net revenue	$ 468,059	$ 338,298	$ 260,981
Advanced Wound Care
Total net revenue	430,839	294,624	220,744
Surgical & Sports Medicine
Total net revenue	$ 37,220	$ 43,674	$ 40,237

Significant Accounting Polici_7

Significant Accounting Policies - Schedule of Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, net	$ 79,160	$ 55,792
Total assets	443,259	290,218
Additional paid-in capital		296,830
Accumulated deficit	(60,133)	(155,035)
Total stockholders' equity	242,035	141,808	$ 52,022	$ 39,939
Total liabilities and stockholders' equity	$ 443,259	290,218
As Previously Reported
Property and equipment, net		60,068
Total assets		294,494
Additional paid-in capital		299,129
Accumulated deficit		(153,058)
Total stockholders' equity		146,084		$ 47,041
Total liabilities and stockholders' equity		294,494
Adjustments
Property and equipment, net		(4,276)
Total assets		(4,276)
Additional paid-in capital		(2,299)
Accumulated deficit		(1,977)
Total stockholders' equity		(4,276)
Total liabilities and stockholders' equity		$ (4,276)

Significant Accounting Polici_8

Significant Accounting Policies - Schedule of Consolidated Statements of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Selling, general and administrative	$ 250,200	$ 204,193	$ 200,088
Total operating expenses	280,942	224,279	214,887
Income from operations	72,918	26,700	(29,854)
Change in fair value of warrant liability			2,140
Total other expense, net	(9,132)	(8,936)	(8,705)
Net income (loss) before income taxes	63,786	17,764	(38,559)
Net income (loss)	94,902	17,234	(38,709)
Non-cash deemed dividend to warrant holders			(568)
Net income (loss) attributed to common shareholders	$ 94,902	$ 17,234	$ (39,277)
Net income (loss), per share:
Basic	$ 0.74	$ 0.16	$ (0.42)
Diluted	$ 0.71	$ 0.15	$ (0.42)
As Previously Reported
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Selling, general and administrative		$ 203,478	$ 199,693
Total operating expenses		223,564	214,492
Income from operations		27,415	(29,459)
Total other expense, net			(10,845)
Net income (loss) before income taxes		18,479	(40,304)
Net income (loss)		17,949	(40,454)
Non-cash deemed dividend to warrant holders			(645)
Net income (loss) attributed to common shareholders		$ 17,949	$ (41,099)
Net income (loss), per share:
Basic		$ 0.17	$ (0.44)
Diluted		$ 0.16	$ (0.44)
Adjustments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Selling, general and administrative		$ 715	$ 395
Total operating expenses		715	395
Income from operations		(715)	(395)
Change in fair value of warrant liability			2,140
Total other expense, net			2,140
Net income (loss) before income taxes		(715)	1,745
Net income (loss)		(715)	1,745
Non-cash deemed dividend to warrant holders			77
Net income (loss) attributed to common shareholders		$ (715)	$ 1,822

Significant Accounting Polici_9

Significant Accounting Policies - Schedule of Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income (loss)	$ 94,902	$ 17,234	$ (38,709)
Depreciation	5,781	4,438	3,783
Change in fair value of warrant liability			(2,140)
Recovery of certain notes receivable from related parties		0
Prepaid expenses and other current assets	(34)	(355)	(625)
Accounts payable	3,847	(4,102)	4,700
Net cash provided by (used in) operating activities	61,978	5,466	(33,528)
Purchases of property and equipment	(31,220)	(17,678)	(5,984)
Proceeds from the repayment of notes receivable from related parties		0
Net cash used in investing activities	$ (31,220)	(23,498)	(6,234)
As Previously Reported
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income (loss)		17,949	(40,454)
Depreciation		3,723	3,388
Recovery of certain notes receivable from related parties		(1,516)
Prepaid expenses and other current assets		(971)
Accounts payable		(635)
Net cash provided by (used in) operating activities		6,801
Purchases of property and equipment		(21,145)
Proceeds from the repayment of notes receivable from related parties		2,132
Net cash used in investing activities		(24,833)
Adjustments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income (loss)		(715)	1,745
Depreciation		715	395
Change in fair value of warrant liability			$ (2,140)
Recovery of certain notes receivable from related parties		1,516
Prepaid expenses and other current assets		616
Accounts payable		(3,467)
Net cash provided by (used in) operating activities		(1,335)
Purchases of property and equipment		3,467
Proceeds from the repayment of notes receivable from related parties		(2,132)
Net cash used in investing activities		$ 1,335

Significant Accounting Polic_10

Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2021	Jul. 22, 2019	Dec. 31, 2018
Significant Accounting Policies [Line Items]
GPO Fees	$ 2,963	$ 3,572	$ 3,096
Restricted Cash, Current	$ 599	412
Equity issuance costs recorded to additional paid-in capital		4,647	3,510
Lease liabilities, Term	12 months
Operating lease liability	$ 58,678			$ 15,935
Right-of-use asset	49,144	0		$ 13,525
Impairment of goodwill	0	0	$ 0
Deferred Income tax benefit	48,252
Common Stock [Member]
Significant Accounting Policies [Line Items]
Common stock issued in warrant exchange (shares)			3,315,232
Private Warrants [Member]
Significant Accounting Policies [Line Items]
Number of Warrants						4,100,000
Public Warrants [Member]
Significant Accounting Policies [Line Items]
Number of Warrants			0		30,890,748	31,000,000
Selling, General and Administrative Expenses
Significant Accounting Policies [Line Items]
Advertising Expense	$ 5,522	$ 2,722	$ 1,059

Acquisition - Additional Inform

Acquisition - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 17, 2020	Dec. 31, 2020	Dec. 31, 2021
Payments​ to acquire businesses gross		$ 5,820
Business Acquisitions, Contingent Consideration Liability Noncurrent	$ 3,782	$ 3,985	$ 0
CPN Biosciences, LLC
Business Acquisitions, Aggregate Consideration	19,024
Payments​ to acquire businesses gross	$ 5,820
Issuance of common stock associated with business acquisition	1,947,953
Business Acquisitions, Liabilities Incurred	$ 1,436
Business Acquisitions, Contingent Consideration Liability Noncurrent	$ 3,782
Earnout Calculation	70.00%
CPN Biosciences, LLC | Total Consideration Including Holdback [Member]
Payments​ to acquire businesses gross	$ 6,427
Common Stock [Member]
Issuance of common stock associated with business acquisition		1,947,953
Common Stock [Member] | CPN Biosciences, LLC | Total Consideration Including Holdback [Member]
Business Acquisitions, Number Of Shares Issued	2,151,438
Business Acquisitions, Equity Interests Issued And Issuable	$ 8,815

Fair Value Measurement of Fin_3

Fair Value Measurement of Financial Instruments - Financial Assets And Liabilities Measured At Fair Value (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Sep. 17, 2020
Liabilities:
Liabilities	$ 0	$ 3,985	$ 3,782
Fair Value, Measurements, Recurring
Liabilities:
Liabilities		3,985
Fair Value, Measurements, Recurring | Earnout Liability [Member]
Liabilities:
Liabilities		3,985
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3
Liabilities:
Liabilities		3,985
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | Earnout Liability [Member]
Liabilities:
Liabilities		$ 3,985

Fair Value Measurement of Fin_4

Fair Value Measurement of Financial Instruments - Fair value of the Company's Earnout liability (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition, Contingent Consideration [Line Items]
Change in fair value	$ (3,985)	$ 203
Fair Value, Inputs, Level 3 | Earnout Liability [Member]
Business Acquisition, Contingent Consideration [Line Items]
Beginning balance	3,985
Acquisition Date fair value		3,782
Change in fair value	(3,985)	203
Ending balance		$ 3,985

Fair Value Measurement of Fin_5

Fair Value Measurement of Financial Instruments - Fair Value Recognized As a Component of Other Expense (Detail) - Warrant [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Balance as of December 31, 2019	$ 3,936
Change in fair value	(2,140)
Settled in warrant exchange transaction	(1,796)
Balance as of December 31, 2020

Fair Value Measurement of Fin_6

Fair Value Measurement of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Sep. 17, 2020	Dec. 31, 2018
Earnout liability		$ 0	$ 3,985	$ 3,782
Change in fair value of warrant liability	$ (2,140)
Private Warrants [Member]
Number of Warrants					4.1
Change in fair value of warrant liability	$ 2,140

Accounts receivable, net (Detai

Accounts receivable, net (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Receivables [Abstract]
Accounts receivable	$ 87,613	$ 59,473
Less—allowance for doubtful accounts	(5,153)	(2,669)
Accounts receivable	$ 82,460	$ 56,804

Accounts receivable, net - Doub

Accounts receivable, net - Doubtful Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance	$ 2,669	$ 1,988
Additions	2,999	1,183	$ 239
Write-offs	(515)	(502)
Balance	$ 5,153	$ 2,669	$ 1,988

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Raw materials	$ 9,023	$ 10,075
Work in process	991	1,305
Finished goods	15,008	16,419
Inventory	$ 25,022	$ 27,799

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory reserve and obsolescence charged to cost of goods	$ 12,079	$ 3,050	$ 1,297

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Subscriptions	$ 2,745	$ 2,013
Conferences and marketing expenses	538	63
Deposits	1,216	1,438
Reimbursement of offering expenses	0	1,009
Insurance	358	240
Other	112	172
Prepaid Expense	$ 4,969	$ 4,935

Property and Equipment, Net (De

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment, Gross	$ 89,433	$ 87,810
Accumulated depreciation and amortization	(57,729)	(73,797)
Property, Plant and Equipment, Net	79,160	55,792
Leasehold improvements
Property, Plant and Equipment, Gross	30,531	39,574
Building
Property, Plant and Equipment, Gross	4,943
Furniture, computers and equipment
Property, Plant and Equipment, Gross	53,959	48,236
Construction in progress
Property, Plant and Equipment, Net	$ 47,456	$ 41,779

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2021
Depreciation expense	$ 5,781	$ 4,438	$ 3,783
Finance leases recorded within leasehold improvements	1,174			$ 22,989
Accumulated depreciation to finance lease asset recorded within leasehold improvement	$ 961			$ 19,250
Leasehold improvements
Finance leases recorded within leasehold improvements		21,689
Accumulated depreciation to finance lease asset recorded within leasehold improvement		$ 18,716

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Identifiable intangible assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Original Cost	$ 58,523	$ 58,523
Accumulated Amortization	(32,850)	(27,901)
Net Book Value	25,673	30,622
Developed technology
Original Cost	32,620	32,620
Accumulated Amortization	(17,709)	(14,330)
Net Book Value	14,911	18,290
Trade names and trademarks
Original Cost	2,080	2,080
Accumulated Amortization	(1,183)	(906)
Net Book Value	897	1,174
Customer relationship
Original Cost	10,690	10,690
Accumulated Amortization	(1,381)	(312)
Net Book Value	9,309	10,378
Independent sales agency network
Original Cost	4,500	4,500
Accumulated Amortization	(4,500)	(4,500)
Patent
Original Cost	7,623	7,623
Accumulated Amortization	(7,623)	(7,623)
Non-compete agreements
Original Cost	1,010	1,010
Accumulated Amortization	(454)	(230)
Net Book Value	$ 556	$ 780

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Estimated future annual amortization expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 4,883
2023	4,918
2024	3,403
2025	3,323
2026	3,043
Thereafter	6,103
Total	$ 25,673	$ 30,622

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill	$ 28,772	$ 28,772
Amortization of Intangible Assets	$ 4,949	$ 3,745	$ 6,043

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Personnel costs	$ 26,865	$ 18,943
Royalties	3,458	2,971
Accrued but unpaid lease obligations and interest	3,963
Other	2,303	2,059
Total Accrued Expenses and Other Current Liabilities	$ 36,589	$ 23,973

Restructuring - Summary of liab

Restructuring - Summary of liability related to the restructuring activities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Cost [Member]
Beginning balance	$ 618	$ 0
Expenses	3,513	618
Cash distributions	(1,614)	0
Ending balance	2,517	618
Facility and Other [Member]
Beginning balance	0	0
Expenses	1,191	0
Cash distributions	(540)	0
Ending balance	$ 651	$ 0

Restructuring - Additional Info

Restructuring - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Oct. 21, 2020USD ($)Employees
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost			$ 7,500
Number of employees to retention Benefits | Employees			65
Restructuring Reserve Current	$ 3,168	$ 618
Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	4,704	618
Employee Cost
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost			$ 4,000
Restructuring Charges	3,513	618
Facility and Other
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost			$ 3,500
Restructuring Charges	$ 1,191	$ 0

Long-Term Debt Obligations (Det

Long-Term Debt Obligations (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Line of credit	$ 0	$ 10,000
Term loan	74,062	60,000
Less debt discount and debt issuance cost	(637)	(290)
Term loan, net of debt discount and debt issuance cost	$ 73,425	$ 59,710

Long-Term Debt Obligations - Fu

Long-Term Debt Obligations - Future payments of term loan (Detail) $ in Thousands	Dec. 31, 2021USD ($)
2022	$ 2,812
2023	4,687
2024	5,625
2025	6,563
2026 and beyond	54,375
Total	$ 74,062

Long-Term Debt Obligations - Ad

Long-Term Debt Obligations - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 06, 2021	Mar. 14, 2019	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2020
Loss on the extinguishment of debt			$ (1,883)	$ (1,862)
Letter of credit sub facility			0		$ 10,000
Financial covenants	Under the 2021 Credit Agreement, the Company is required to comply with certain financial covenants including the Consolidated Fixed Charge Coverage Ratio and Consolidated Total Net Leverage Ratio, tested quarterly. In addition, the Company is also required to make representations and warranties and comply with certain non-financial covenants that are customary in loan agreements of this type, including restrictions on the payment of dividends, repurchase of stock, incurrence of indebtedness, dispositions and acquisitions.
Secured debt			74,062		$ 60,000
Term loan repayment			938
ML Agreement [Member]
Loss on the extinguishment of debt				$ 1,862
Repayment under master lease agreement		$ 17,649
2019 Credit Agreement
Loss on the extinguishment of debt			1,883
Term loan repayment	$ 70,559
2021 Credit Agreement | Euro Dollar Loans [Member] | Applicable Margin [Member] | Maximum [Member]
Debt instrument interest and applicable margin rate percentage	3.25%
2021 Credit Agreement | Euro Dollar Loans [Member] | Applicable Margin [Member] | Minimum [Member]
Debt instrument interest and applicable margin rate percentage	2.00%
2021 Credit Agreement | Abr Loans [Member]
Debt Instrument, Description of Variable Rate Basis	For Eurodollar Loans, the interest rate is a per annum interest rate equal to LIBOR plus an Applicable Margin between 2.00% to 3.25% based on the Total Net Leverage Ratio. For ABR Loans, the interest rate is equal to (1) the highest of (a) the Wall Street Journal Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) the LIBOR rate plus 1.0%, plus (2) an Applicable Margin between 1.00% to 2.25% based on the Total Net Leverage Ratio.
2021 Credit Agreement | Abr Loans [Member] | Applicable Margin [Member] | Maximum [Member]
Debt instrument, interest rate, effective percentage	2.25%
2021 Credit Agreement | Abr Loans [Member] | Applicable Margin [Member] | Minimum [Member]
Debt instrument, interest rate, effective percentage	1.00%
Term Loan [Member] | 2019 Credit Agreement
Debt Instrument, Basis Spread on Variable Rate		3.75%
Debt Instrument, Description of Variable Rate Basis		annum interest rate equal to the greater of 3.75% above the Wall Street Journal Prime Rate and 9.25%
Additional Payment in Aggregate of the Principal Amount Percentage		6.50%
Fixed interest rate		9.25%
Debt instrument, face amount		$ 40,000
Debt instrument maturity date		2024
Term Loan [Member] | 2021 Credit Agreement
Secured debt			74,062
Debt Issuance Costs, Net	$ 604
Prepayment Premium	1.00%
Debt instrument, face amount	$ 75,000
Term Loan [Member] | 2021 Credit Agreement | September 30, 2021 through and including June 30, 2022
Debt instrument consecutive quarterly installment payments equal to percentages of the original principal amount of the Term Loans	0.625%
Debt instrument quarterly installment payment to original principal amount	$ 469
Term Loan [Member] | 2021 Credit Agreement | September 30, 2022 through and including June 30, 2023
Debt instrument consecutive quarterly installment payments equal to percentages of the original principal amount of the Term Loans	1.25%
Debt instrument quarterly installment payment to original principal amount	$ 938
Term Loan [Member] | 2021 Credit Agreement | September 30, 2023 through and including June 30, 2025
Debt instrument consecutive quarterly installment payments equal to percentages of the original principal amount of the Term Loans	1.875%
Debt instrument quarterly installment payment to original principal amount	$ 1,406
Term Loan [Member] | 2021 Credit Agreement | September 30, 2025 and the last day of each quarter thereafter until August 6, 2026
Debt instrument consecutive quarterly installment payments equal to percentages of the original principal amount of the Term Loans	2.50%
Debt instrument quarterly installment payment to original principal amount	$ 1,875
Revolving Credit Facility [Member] | 2019 Credit Agreement
Maximum borrowing capacity		$ 60,000
Line of credit maturity date		2024
Line of credit description of variable rate basis for advances under revolving facility		The interest rate for advances under the revolving facility was a floating per annum interest rate equal to the greater of the Wall Street Journal Prime Rate and 5.50%
Revolving Credit Facility [Member] | 2021 Credit Agreement
Maximum borrowing capacity	$ 125,000		125,000
Debt Issuance Costs, Net			$ 1,223
Prepayment premium percentage	1.00%
Revolving Credit Facility [Member] | 2021 Credit Agreement | Maximum [Member]
Line​ of credit ​facility​ unused​ capacity​ commitment​ fee​ percentage	0.45%
Revolving Credit Facility [Member] | 2021 Credit Agreement | Minimum [Member]
Line​ of credit ​facility​ unused​ capacity​ commitment​ fee​ percentage	0.25%

Stockholders' Equity (Detail)

Stockholders' Equity (Detail) - shares	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Shares reserved for issuance for outstanding options	6,596,969	6,425,040
Shares reserved for issuance for outstanding restricted stock units	764,871	806,048
Shares reserved for issuance for future grants	5,644,691	6,832,649
Total shares of authorized common stock reserved for future issuance	13,006,531	14,063,737

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended	12 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Mar. 24, 2019	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jul. 22, 2019	Dec. 31, 2018
Common stock, par value					$ 0.0001	$ 0.0001
Common stock, shares issued					129,408,740	128,460,381
Non-cash deemed dividend to warrant holders							$ 568,000
Aggregate Purchase Price of Class A common stock						$ 64,729,000	$ 50,340,000
Reimbursement of offering expenses included in prepaid expenses and other current assets					$ 0	1,009,000
Cash dividend					$ 0
Put Option
Warrants, Exercise price			$ 9.28
Public Warrants [Member]
Warrant exchanged for common stock								29,950,150
Warrants outstanding				0			0		30,890,748	31,000,000
Number Of Securities Called By Each Warrant								0.095
Common stock issuable upon warrant exercise								2,845,280
Private Warrant [Member]
Warrants outstanding										4,300,000
Private Placement Warrants
Warrants outstanding									4,100,000
Number Of Securities Called By Each Warrant								0.095
Common stock issuable upon warrant exercise								389,501
Twenty Thousand Nineteen Underwritten Public Offering [Member]
Common stock, shares issued		10,068,056
Aggregate Purchase Price of Class A common stock		$ 50,340,000
Common stock price per share		$ 5
Shares offered in the underwritten public offering		9,000,000
Proceeds from issuance of common stock net of offering expense		$ 46,831,000
Other offering expense		$ 3,510,000
2020 Underwritten Public Offering [Member]
Common stock, shares issued	19,916,708
Aggregate Purchase Price of Class A common stock	$ 64,729,000
Common stock price per share	$ 3.25
Shares offered in the underwritten public offering	17,500,000
Proceeds from issuance of common stock net of offering expense	$ 59,073,000
Other offering expense	4,647,000
Reimbursement of offering expenses included in prepaid expenses and other current assets	1,009,000
2020 Underwritten Public Offering [Member] | Other Current Assets [Member]
Other offering expense	$ 5,656,000
Amendment To The Warrant Agreement [Member]
Number Of Securities Called By Each Warrant								0.0855
Common stock issuable upon warrant exercise								80,451
Common Class A
Common stock, par value	$ 0.0001	$ 0.0001
Company issued acquisition of shares			728,548
Non-cash deemed dividend to warrant holders				$ 568,000
Aggregate Purchase Price of Class A common stock						$ 64,729,000	$ 50,340,000
Common stock voting rights					one
Redeemable Common Stock | Nutech Acquisition [Member]
Company issued acquisition of shares			728,548

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair value of option vested	$ 813	$ 678
Unrecognized stock compensation expense	$ 3,998
Share-based compensation expected to be recognized over a weighted-average period	2 years 11 months 1 day
Weighted average grant-date fair value	$ 5.32	$ 1.05
Number of options exercised	955,736
Restricted Stock Units [Member]
Unrecognized stock compensation expense	$ 3,273
Share-based compensation expected to be recognized over a weighted-average period	2 years 8 months 19 days
Restricted stock units issued to employees	310,692
Option Loans
Related Parties Notes Receivable		$ 334	$ 635
Number of shares issued as collateral for the option loans			675,990
Number of options exercised	195,278
Selling, General and Administrative Expenses
Share-based compensation expense	$ 3,864	$ 1,661	$ 936
2018 Stock Incentive Plan
Stock option expiration period	10 years
2003 and 2018 Stock Incentive Plan | Maximum
Stock awards granted vesting period	5 years
2003 and 2018 Stock Incentive Plan | Minimum
Stock awards granted vesting period	4 years
Common Class A | 2018 Stock Incentive Plan
Common stock options authorized	9,198,996

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Fair Value of Stock Options Granted to Employees and Directors (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Risk-free interest rate	0.83%	0.46%
Expected term (in years)	6 years 2 months 19 days	6 years 2 months 19 days
Expected volatility	39.31%	37.42%
Expected dividend yield	0.00%	0.00%
Exercise price	$ 13.57	$ 4.04
Underlying stock price	$ 13.57	$ 3.37

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Restricted Stock Units (Detail) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at December 31, 2019 | shares	787,923
Unvested Granted | shares	310,692
Unvested Vested | shares	(248,305)
Unvested Canceled/Forfeited | shares	(85,439)
Unvested at December 31, 2020 | shares	764,871
Unvested at December 31, 2019 | $ / shares	$ 3.81
Unvested Granted | $ / shares	14.29
Unvested Vested | $ / shares	4.20
Unvested Canceled/Forfeited | $ / shares	7.64
Unvested at December 31, 2020 | $ / shares	$ 7.52

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Shares Outstanding	6,615,223
Number of Shares Granted	1,069,658	1,553,723
Number of Shares Exercised	(955,736)
Number of Shares Canceled / forfeited	(132,176)
Number of Shares Outstanding	6,596,969	6,615,223
Number of Shares Options Exercisable	4,342,519
Number of Shares Options vested or expected to vest	6,216,308
Weighted Average Exercise Price Outstanding	$ 2.32
Weighted Average Exercise Price Granted	13.57
Weighted Average Exercise Price Exercised	2.29
Weighted Average Exercise Price Cancelled / forfeited	4.67
Weighted Average Exercise Price Outstanding	4.10	$ 2.32
Weighted Average Exercise Price Options Exercisable	1.80
Weighted Average Exercise Price Options Vested or Expected to Vest	$ 3.79
Weighted Average Remaining Contractual Term (in years) Outstanding	5 years 2 months 12 days	5 years 2 months 19 days
Weighted Average Remaining Contractual Term (in years) Options Exercisable	3 years 5 months 19 days
Weighted Average Remaining Contractual Term (in years) Options Vested or Expected to Vest	4 years 11 months 23 days
Aggregate Intrinsic Value Outstanding	$ 38,524	$ 34,438
Aggregate Intrinsic Value Options Exercised	10,121
Aggregate Intrinsic Value Options Exercisable	32,292
Aggregate Intrinsic Value Options Vested or Expected to Vest	$ 37,618

Share-Based Compensation - Pare

Share-Based Compensation - Parenthetical (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Options granted	1,069,658	1,553,723

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal		$ (106)	$ (105)
State	$ 899	505	116
Foreign	(39)	19	28
Total current tax expense (benefit)	860	418	39
Deferred tax expense (benefit)
Federal	(30,506)	109	105
State	(1,470)
Foreign		3	6
Total deferred tax expense	(31,976)	112	111
Total income tax expense	$ (31,116)	$ 530	$ 150

Income Taxes - Component of Com

Income Taxes - Component of Company's Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]
Federal	$ 21,760	$ 31,783
State	1,612	3,342
Foreign	16	18
Other	7,556	5,829
163j interest		4,979
Stock-based compensation	676	357
Finance leases	632	2,991
Operating leases	12,918
Fixed assets	2,748	2,589
Net deferred tax assets before valuation allowance	47,918	51,888
Deferred tax assets valuation allowance		(48,252)
ROU assets	(12,273)
Intangibles	(3,651)	(3,618)
Net deferred tax assets	$ 31,994	$ 18

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
U.S. federal statutory income tax rate	21.00%	21.00%	21.00%
Federal valuation allowance	(70.60%)	(28.90%)	(17.60%)
State valuation allowance	(9.10%)	(4.80%)	(3.90%)
State and local income taxes	6.80%	6.20%	3.50%
Nondeductible expenses	0.80%	6.00%	(1.40%)
Uncertain tax position reserves	0.90%	0.40%	(0.10%)
Research and development credits	0.90%	3.00%	(1.90%)
Effective income tax rate	(49.30%)	2.90%	(0.40%)

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Gross balance at beginning of year	$ 2,123	$ 2,618	$ 3,286
Additions based on tax positions related to the current period	153	111	133
Reductions for tax positions of prior years	(664)	(606)	(801)
Gross balance at end of year	$ 1,612	$ 2,123	$ 2,618

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Federal corporate income tax rate	21.00%	21.00%	21.00%
Operating loss carryforwards research and development credit	$ 1,003
Unrecognized tax benefits	$ 2,307	$ 2,870	$ 3,192
Description of tax benefits upon ultimate settlement	The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.
Income tax penalities and interest expense	$ 330	$ 317
Operating loss carryforward indefinately	58,481
Deferred income tax (expense) benefit	48,252
Subsidiaries [Member]
Net operating loss cary forward	16
Domestic Tax Authority [Member]
Operating Loss Carryforwards	103,619
Domestic Tax Authority [Member] | Expiration December 31, 2021 through 2037
Operating Loss Carryforwards	$ 45,138
Domestic Tax Authority [Member] | Minimum
Operating loss carryforward expiration term	Dec. 31, 2021
Tax credit carryforward expiration term	Dec. 31, 2021
Domestic Tax Authority [Member] | Maximum
Operating loss carryforward expiration term	Dec. 31, 2037
Tax credit carryforward expiration term	Dec. 31, 2037
State and Local Jurisdiction [Member] | Expiration December 31, 2021 through 2039
Operating Loss Carryforwards	$ 25,431

Net Income (Loss) Per Share (_3

Net Income (Loss) Per Share (EPS) - Basic and diluted net loss per share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net Income (loss)	$ 94,902	$ 17,234	$ (38,709)
Less: Non-cash dividend to warrant holders			568
Net Income (loss) attributable to common shareholders	$ 94,902	$ 17,234	$ (39,277)
Weighted-average common shares outstanding—basic	128,331,022	107,737,936	92,840,401
Weighted-average common shares outstanding—diluted	133,662,659	111,360,831	92,840,401
Earnings (loss) per share—basic	$ 0.74	$ 0.16	$ (0.42)
Earnings (loss) per share—diluted	$ 0.71	$ 0.15	$ (0.42)
Restricted Stock Units [Member]
Dilutive effect of awards	469,123	135,932
Employee Stock Option
Dilutive effect of awards	4,862,514	3,486,963

Net Income (Loss) per Share (_4

Net Income (Loss) per Share (EPS) - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Anti-dilutive shares excluded from the diluted EPS	994,168	1,792,085	7,179,636

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Cost (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Leases [Abstract]
Finance lease Amortization of right-of-use assets	$ 1,707
Finance lease Interest on lease liabilities	980
Total Finance lease cost	2,687
Operating lease cost	7,066
Short-term lease cost	2,869
Variable lease cost	4,808
Total lease cost	$ 17,430

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	Aug. 31, 2021USD ($)	Mar. 31, 2019USD ($)ft²	Dec. 31, 2021USD ($)ft²	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Lessee, Operating Lease, Term of Contract			12 months
Land Subject to Ground Leases | ft²		43,850
Security Deposit		$ 526
Annual Lease payments During the first year		1,052
Annual lease payments ten year lease term		44
Annual lease payments five year lease term		33
Increase (Decrease) in Security Deposits		$ 263
Operating lease, expense				$ 6,509	$ 6,231
Property plant and equipment net			$ 79,160	55,792
Accrued But Unpaid Capital Lease Obligation | Principal Interest and C A M [Member]
Total accrued but unpaid lease obligations			$ 7,804	$ 10,336
275 Dan Road SPE LLC [Member] | 275 Dan Road Building [Member]
Purchase of building under the lease amount	$ 6,013
Percentage of amount required to pay for the accrued but unpaid lease obligations associated with building	50.00%
Interest on the balance of the accrued but unpaid lease obligations associated with building was reduced to annula simplete rate,Percentage			4.50%
Cash payment in excess of the lease liability	$ 4,535
Net book value of right of use asset removed from leasehold improvement	408
275 Dan Road SPE LLC [Member] | 275 Dan Road Building [Member] | Building [Member]
Property plant and equipment net	$ 4,943
California
Lessee, Operating Lease, Term of Contract			10 years
Lessee, Operating Lease, Option to Extend			five years
Land Subject to Ground Leases | ft²			23,000
Security Deposit			$ 237
Aggregate​ annual lease payments rent​ percentage increases			3.00%
Annual Lease payments During the first year			$ 1,562
Fleet Lease [Member]
Lessee, Operating Lease, Term of Contract			367 days
Maximum [Member]
Lessee, Operating Lease, Renewal Term			10 years
Minimum [Member]
Lessee, Operating Lease, Renewal Term			5 years

Leases - Summary of Balance She

Leases - Summary of Balance Sheet Information Related To Finance Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
Lessee Disclosure [Abstract]
Property and equipment, gross	$ 1,174	$ 22,989
Accumulated depreciation	(961)	(19,250)
Property and equipment, net	213	3,739
Current portion of finance lease obligations	200	3,619	$ 3,619
Finance lease long-term obligations	0	11,442	$ 11,442
Total lease liabilities	$ 200	$ 15,061
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Current portion of finance lease obligations

Leases - Schedule of Accrued bu

Leases - Schedule of Accrued but Unpaid Lease Obligations (Detail) - Accrued But Unpaid Capital Lease Obligation [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Accrued But Unpaid Lease Obligations [Line Items]
Accrued interest on accrued but unpaid lease obligations	$ 1,938	$ 1,673
Principal [Member]
Schedule Of Accrued But Unpaid Lease Obligations [Line Items]
Total accrued but unpaid lease obligations	7,246	6,946
Principal Interest and C A M [Member]
Schedule Of Accrued But Unpaid Lease Obligations [Line Items]
Total accrued but unpaid lease obligations	7,804	10,336
Interest [Member]
Schedule Of Accrued But Unpaid Lease Obligations [Line Items]
Total accrued but unpaid lease obligations		2,865
CAM [Member]
Schedule Of Accrued But Unpaid Lease Obligations [Line Items]
Total accrued but unpaid lease obligations	$ 558	$ 525

Leases - Summary of Cash Flow I

Leases - Summary of Cash Flow Information Related To Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]
Operating cash flows for operating leases	$ 7,276
Operating cash flows for finance leases	1,427
Financing cash flows for finance leases	2,630	$ 2,427	$ 1,266
Right-of-use assets obtained in exchange for lease obligations - upon adoption:
Operating leases	$ 53,793		$ 1,099
Weighted-average remaining lease term
Finance leases	5 months 12 days
Operating leases	8 years 2 months 19 days
Weighted-average discount rate
Finance leases	11.30%
Operating leases	4.51%
Post Adoption [Member]
Right-of-use assets obtained in exchange for lease obligations - upon adoption:
Operating leases	$ 40,268
Upon Adoption [Member]
Right-of-use assets obtained in exchange for lease obligations - upon adoption:
Operating leases	$ 13,525

Leases - Summary of Maturities

Leases - Summary of Maturities of Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Jan. 01, 2021
Lessee Disclosure [Abstract]
2022	$ 14,032
2023	8,100
2024	7,315
2025	7,526
2026	7,435
Thereafter	25,936
Total lease payments	70,344
Less: interest	(11,666)
Total lease liabilities	58,678	$ 15,935
2022	207
2023	0
2024	0
2025	0
2026	0
Thereafter	0
Total lease payments	207
Less: interest	(7)
Total lease liabilities	$ 200	$ 15,061

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	Feb. 14, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017
Accrued Legal Expenses		$ 150	$ 150
Gain on litigation settlement			2,246
Selling, General and Administrative Expenses
Royalty Expense		5,929	4,370	$ 3,778
License Agreement University
Accrued Royalties		1,187	1,187
Royalty Expense		$ 0	$ 0	$ 0
NuTech Medical
Deferred Acquisition Cost Paid					$ 2,500
The amount, if any, of the remaining $5,000 of deferred acquisition consideration plus accrued interest owed to the sellers of NuTech Medical is currently in dispute.					5,000
Business Combination Deferred Consideration					$ 7,500
Agreement cancellation charges paid	$ 1,950
Consulting service and royalty payment term	15 years
Damages awarded	$ 4,000
Loss contingency damages paid	2,000
Loss contingency value of each instalment to be paid	500
Loss contigency damages payable	$ 2,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Selling, General and Administrative Expenses
Related Party Transaction, Amounts of Transaction		$ 179
Option Loans
Related Parties Notes Receivable		334	$ 635
Proceeds from Collection of Long-term Loans to Related Parties	$ 334
Liquidity Loan [Member]
Related Parties Notes Receivable		$ 100
Maximum [Member] | Liquidity Loan and Option Loans
Interest Rate	3.86%
Minimum [Member] | Liquidity Loan and Option Loans
Interest Rate	2.30%

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Company made employer contributions	$ 3,092	$ 2,731	$ 2,290

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,069,658	1,553,723
Restricted Stock Units [Member]
RSU granted during the period		310,692
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award vesting period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,126,157
Subsequent Event [Member] | Restricted Stock Units [Member]
RSU granted during the period	495,389